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Abstract
Alzheimer disease is considered to be a progressive neurodegenerative condition,
clinically characterized by cognitive dysfunction and memory impairments. Incorporating
imaging biomarkers in the early diagnosis and monitoring of disease progression is
increasingly important in the evaluation of novel treatments. The purpose of the work in
this thesis was to develop and evaluate novel structural and functional biomarkers of
disease to improve Alzheimer disease diagnosis and treatment monitoring. The
overarching hypothesis is that magnetic resonance imaging methods that sensitively
measure brain structure and functional impairment have the potential to identify people
with Alzheimer’s disease prior to the onset of cognitive decline. Since the hippocampus
is considered to be one of the first brain structures affected by Alzheimer disease, in the
first study a reliable and fully automated approach was developed to quantify medial
temporal lobe atrophy using magnetic resonance imaging. This measurement of medial
temporal lobe atrophy showed differences (p<0.05) between groups of healthy people,
people with mild cognitive impairment and people with Alzheimer disease. In the second
study, a novel biomarker of brain activity was developed based on a first-order textural
feature of the resting state functional magnetic resonance imagining signal. The mean
brain activity metric was shown to be significantly lower (p<0.05) within specific brain
regions in people with Alzheimer’s disease compared to healthy subjects and was
correlated with cognitive performance and CSF biomarkers. Interestingly, this brain
activity metric was also correlated (p<0.05) with glucose metabolism in each subject
measured using

18

F labeled fluorodeoxyglucose positron emission tomography. In the

final study, we examine whether combined measures of gait and cognition could predict
medial temporal lobe atrophy over 18 months in a small cohort of people (N= 22) with
mild cognitive impairment. The results showed that measures of gait impairment can
help to predict medial temporal lobe atrophy in people with mild cognitive impairment.
The work in this thesis contributes to the growing evidence that specific magnetic
resonance imaging measures of brain structure and function can be used to identify and
monitor the progression of Alzheimer’s disease. Continued refinement of these methods,
and larger longitudinal studies will be needed to establish whether the specific metrics of
brain dysfunction developed in this thesis can be of clinical benefit and aid in drug
development.

Keywords:
Alzheimer disease, Mild cognitive impairment, Biomarkers, Medial temporal lobe, Brain
activity, Magnetic resonance imaging, Resting state function magnetic resonance
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Chapter 1: Thesis Introduction
The overall goal of this thesis is to develop and evaluate novel structural and
functional magnetic resonance imaging (MRI) biomarkers of Alzheimer’s disease. Such
biomarkers are required to monitor disease progression and may help identify people at
risk for the disease. The search for sensitive and specific early indicators of Alzheimer’s
disease (AD) prior to symptom onset has intensified over the last decade. The work in
this thesis contributes to a growing literature that has identified specific structural and
functional abnormalities in the brain associated with AD and Mild Cognitive Impairment
(MCI). Specifically, in the first study a novel tissue segmentation method was developed
to characterize volume changes in the medial temporal lobe (mainly hippocampus) in
subjects with MCI and AD. In the second study a new biomarker of neuronal activity was
developed using blood oxygen level dependent (BOLD) contrast fluctuation during
resting state functional MRI and was used to demonstrate reduced activity in subjects
with AD compared to healthy controls. Finally, in the third study the medial temporal
lobe segmentation method developed in the first study was used to classify a cohort of
MCI subjects as stable or in decline to determine whether measures of gait and cognition
could predict MTL atrophy over 18 months.

This first chapter introduces the

neuropathology, diagnosis and clinical assessment of AD, and imaging biomarkers
currently in development to predict the early stages of the disease, and to evaluate disease
progression. This chapter also provides a background to image registration and
segmentation theory, and describes aspects of MRI relevant to the processing and
analysis chapters that follow.

2
1.1 Alzheimer Disease
Alzheimer disease (AD) is a progressive neurodegenerative disease of the brain and
is the most common cause of dementia. AD causes symptoms of dementia such as
memory loss, difficulty performing daily activities, and changes in judgement, reasoning,
behaviour, and emotions. There are three main categories of AD. First is familial AD
(FAD), which is caused by mutations in specific genes. The second is early-onset AD,
which affects people younger than 65. The third is late-onset AD, which appears in adults
aged 65 and older (Alzheimer society of Canada, 2014). AD affects approximately 10%
of people who are less than 65 years old and the incidence approximately doubles every 5
years up to age 80.1 Current estimates suggest half a million Canadian individuals are
diagnosed with AD and 24 million people are afflicted by AD worldwide (Alzheimer’s
Society of Canada, January 2009). AD progresses gradually and is classified into three
main stages based on the symptoms. The early (mild) stage corresponds to the first
diagnosis of the disease and usually lasts for 2 to 4 years. Common symptoms include
difficulty recalling new information, problem solving, and subtle personality changes.
The moderate stage is the longest in duration and typically lasts 2 to 10 years. Subjects
have increased difficulty with memory and may need help with their daily activities.
Usual symptoms include increasingly poor judgment, difficulty performing complex
tasks, greater memory loss and significant personality changes. The last stage is the most
severe and usually lasts 1 to 3 years. Cognitive function and physical ability are
significantly impacted. Common symptoms include the inability to communicate,
difficulty with personal care, and the inability to perform basic physical functions.2,3
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AD is the only cause of death among the top 10 causes that has no known prevention
or cure.4,5 Future morbidity and mortality of people with AD could be reduced by
defining reliable diagnostic biomarkers that could be used to detect the disease early.
Early knowledge of the disease should provide people with an opportunity to modify the
progression of the disease if and when there is an effective treatment developed. Figure
1.1 provides a schematic overview of brain structure labeled with associated functions.

1.2 Mild Cognitive Impairment
Mild cognitive impairment (MCI) is a transitional stage between normal aging and
Alzheimer disease and is considered by some to be a symptomatic pre-dementia phase.
Cognitive and behavioral impairment is characterized by impairment within a minimum
of two cognitive domains: memory, executive function (e.g. reasoning, problem solving,
planning), language (e.g. naming, fluency, expressive speech), attention, and visuospatial
skills (e.g. simple and divided attention).6 Impairment in episodic memory is one of the
clinical indicators7 of MCI and is a strong predictor of conversion to AD.

4

Figure 1.1 Anatomy of brain structures in sagittal view
This schematic shows 4 lobes and structures in the brain along with their functions.[1]

The number of people with MCI aged 75 years and younger is 19%, while 29% of
people who are 85 years and older are characterized by a cognitive decline without
impairment in the performance of the activities of daily living.8 The prevalence of
amnestic MCI (aMCI) diagnosed by memory impairment and delayed recall but normal
test result on other cognitive domains9,10 is 30% among individuals with MCI. The
incidence of conversion of aMCI to AD is approximately 12% each year, and up to 80%
have progression to AD after 6 years.9 Therefore, it is imperative that accurate methods
are developed to identify subjects with MCI that will progress to AD so that when
developed, disease-modifying treatment could be used to avoid significant brain damage.

[1]

Adapted with permission from: // http://www.brainwaves.com/
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1.3 Neuropathology
Theories about the neuropathology of AD involve mostly two specific proteins:
amyloid beta (Aβ) and tau. Specifically, these two proteins lead to the formation of Aβ
plaques and neurofibrillary tangles (NFT), which accumulate abnormally11,12 during
aging and in AD. The prevalence of the aggregation increases gradually with age and
these remain the main pathological hallmarks of the disease.
Aβ plaques are found outside of neurons (extracellular) and consist of Aβ peptides
with 40-42 amino acids (Aβ40 and Aβ42). Aβ peptides are produced by metabolism of the
amyloid precursor proteins (APPs) that are cleaved by the enzymes β- and γ-secretases in
the neuron.13,14 Soluble Aβ monomers aggregate into oligomers and re-arrangement of
these oligomers produce β-sheets and fibrils.15 Aβ plaques are divided into two groups
called diffuse and dense (neuritic) based on their staining with dyes specific for the βsheet (e.g., Congo red and Thioflavin-S).14,16 Dense plaques are stained with dyes but
diffuse plaques are negative. Diffuse plaques are non-fibrilar accumulations of Aβ and
are not associated with detectable dystrophic neurites, synaptic loss, or neuron loss.
Diffuse plaques are also found in the cortex of cognitively normal aged people.17 While
dense plaques contain fibrilary Aβ and are surrounded by degenerating axons and
dendrites that are most often found in AD subjects. Aβ plaques are toxic in close
proximity to nerve cells and promote the hyperphosphorylation of the tau protein.
The aggregation of hyperphosphorylated tau protein leads to the formation of NFTs
inside neurons (intracellular). Tau is a phosphorprotein normally localized to the axon,
where it physiologically aids in axonal transport by binding and stabilizing the
microtubules in the cell cytoskeleton. In AD patients, tau is displaced to the

6
somatodendritic compartment and undergoes hyperphosphorylation, misfolding, and
aggregation in neurons. Paired helical filaments are the predominant form of NFTs.18
The overall effects of Aβ plaques and NFTs are to produce synaptic failure and
neuronal loss, which are the main pathological hallmarks of AD. This link is critical since
brain structure and atrophy can be measured using MRI. Cortical atrophy occurs
gradually and eventually produces declines in cognitive and executive function.12 Figure
1.2 summarizes the steps involved in the process of Aβ aggregation and NFTs
accumulation in AD. Previous studies have shown an association between the number of
NFT and neuronal loss;19 as well as between Aβ plaque accumulation and neuronal loss.20
Aβ accumulation includes three stages based on the Braak and Braak staging system.17,21
During Stage A, initial depositions can be found in the basal portions of the frontal,
temporal and occipital lobes. During Stage B, all isocortical areas are affected and the
hippocampal formation is mildly involved. But, in this stage, the primary sensory and
motor areas contain none or only small deposits. Stage C is the last stage in which
depositions are found in all areas of the isocortex including visual, sensory and motor
cortex.Based on the Braak and Braak staging system,21 NFT depositions appear first in
the trans-entorhinal region of the temporal lobe, and lateral to the hippocampus (stages I
and II) then spread to the limbic area (stages III and IV), and finally to isocortical areas
(stages V and VI). The progression of regional tau deposition is closely coupled with the
profile of neurocognitive impairment observed in AD.22,23 In addition, NFT accumulation
is more strongly correlated with the severity of cognitive decline compared to Aβ plaques
depositions.14,24 Figure 1.3 demonstrates the Braak and Braak staging of Aβ aggregation
and NFT accumulation during aging.

7

Figure 1.2 The accumulation of Aβ and NFTs in the AD brain
Aβ aggregates surround neurons and neurofibrillary tangles (NFTs) deposit inside neurons. Both
pathologies are associated with dementia.[2] Aβ peptides are produced by metabolism of the
amyloid precursor protein (APPs) that is enzymatically cleaved. Aβ monomers aggregate into
oligomers and re-arrangement of these oligomers produce Aβ fibrils and plaques. Tau becomes
hyperphosphorylated, misfolds, and aggregates in neurons. Paired helical filaments of tau are the
predominant constituents of NFTs. The overall effect of Aβ plaques and NFTs is to produce
synaptic failure and neuronal loss.

[2]

Adapted from Dementia & Neuropsychologia, 3 (2009), V. Paula And F. M.
Guimaraes, Neurobiological pathways to Alzheimer’s disease Amyloid-beta, Tau protein
or both?, 118-194, © 2016
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Figure 1.3 Neuropathology of NFT and Aβ accumulation during aging

Images adopted from Braak and Braak stages.25 The first row indicates the frequency of cases
devoid of changes in relation to the total number of cases in the various age categories. The
second, third, and fourth rows show the progression of amyloid (left panel) and NFT (right panel)
changes during stages (A-C and I-VI). Stages (A) include basal portions of isocortex, (B)
neocortical areas and the hippocampus, and (C) primary areas of the neocortex. Stages (I, and II)
include transentorhinal region, (III, and IV) limbic system and severe involvement in
[3]
transentorhinal and entorhinal regions, (V, and VI) isocortical area.

1.4 Diagnosis and Clinical Assessment
The diagnosis of AD is only confirmed by brain autopsy after death. However, the
National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)
and the Alzheimer’s Disease and Related Disorders Association (ADRDA) established
[3]

Adapted from Neurobiology of Aging, 18 (1996), H. Braak And E. Braak, Frequency
of Stages of Alzheimer-Related Lesions in Different Age Categories, 351-357, © 2016,
with permission from Elsevier
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and described the clinical criteria for AD diagnosis.6 The clinical diagnosis of AD
combines cognitive tests, with physical and neuropsychological exams. Neurological
examination and laboratory tests of thyroid imbalanced calcium and vitamin B12 levels
also help to exclude other causes of dementia.26 The cognitive tests allow physicians to
evaluate changes in cognition in the individual over time. Examples of clinical
neuropsychological assessments include: Rey Auditory Verbal Learning Test (episodic
memory),27

the

Trail

Making

Test

B

(executive

function),28,29

Digit

Span

Forward/Backward and Trail Making Test A (attention and processing),29,30 the Boston
Naming Test (language)31 and Figure Copying (visuospatial skills)32 to assess different
cognitive domains. The evidence of progressive changes of all tests over time is an
important component for accurate diagnosis. The sensitivity of AD diagnosis based on
clinical confidence levels and neuropathological confidence levels varied from 70.9% to
87.3% with specificity ranged from 44.3% to 70.8%.33 Therefore, although such
cognitive testing can help to identify people with AD, diagnostic accuracy might be
improved by the incorporation of additional biomarkers including cerebral spinal fluid
(CSF) and neuroimaging biomarkers.
One of the most common clinical cognitive tests is the mini mental state examination
(MMSE). It is used for diagnosis and to monitor the progression of cognitive
performance over time.34 The test consists of 11 questions and assesses five cognitive
domains including orientation, registration, attention, recall, and language. The maximum
score is 30 and a score of 23 or lower indicates cognitive impairment. The second clinical
cognitive test that is commonly used is the Alzheimer disease assessment scale-cognitive
(ADAS-Cog)35 which includes 11 items involving memory, orientation, language, and
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praxis. This score ranges from 70 (severe impairment) to 0 (no impairment). The MMSE
score has high test-retest reliability, which varies from 0.79 to 0.99.36 Although the
MMSE score is insensitive to MCI37 and has only modest sensitivity to AD with little
diagnostic specificity38 it is still widely used in clinical settings.

1.5 Biomarkers of Alzheimer Disease
A biomarker refers to a measurable indicator of a biological, pathogenic, or
pharmacologic processes that can be used to increase diagnostic sensitivity and
specificity. Biomarkers are particularly critical for early disease detection, disease
staging, and monitoring of disease progression or treatment responses.39 Biomarkers may
be divided into three different categories in relation to the diagnosis of AD. First, some
hallmarks directly reveal the molecular neuropathology of AD. For example, Aβ plaques
and NFT are established hallmarks of the pathological diagnosis of AD. These proteins
can be measure directly from CSF or positron emission tomography (PET) scanning with
several tracers.40-42 Second, biomarkers associated with neural loss and synaptic failure
can be obtained from structural and functional measurements. These include global and
regional brain atrophy measurements using MRI and glucose metabolism measurements
using PET.43-45 The third group is related to biochemical changes including inflammation
and oxidative stress that can be detected using CSF, plasma, and imaging markers.46
Importantly, biomarkers can be used to indicate relevant information about the
underlying disease pathology before the cognitive symptoms progress to dementia.47,48
Biomarkers including cerebral spinal fluid (CSF) Aβ, tau, and p-tau levels, and imaging
methods of brain amyloid, metabolism, and atrophy do not as of yet have standardized
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protocols in place and are mainly applied in research settings.49 The accumulation of
NFTs and Aβ can be measured in CSF and serum;50 the level in CSF is related to cerebral
Aβ aggregation (lower CSF Aβ) and NFT deposits (increased CSF tau, p-tau). The CSF
biomarkers (Aβ1-42, tau and phospho-tau-181) represent a method with high sensitivity
and specificity of 85% to 90% for the diagnosis of AD.51-54 CSF reveals metabolic
processes in the brain due to the close proximity between the brain and CSF. However,
the use of CSF biomarkers is limited because it requires an invasive assessment by
lumbar puncture.51
In addition, PET scanning with a variety of tracers now provides a tool to directly
detect NFTs and Aβ accumulation in the brain. The success of PET Aβ imaging with
Pittsburgh compound B (PiB) has translated into the clinical setting as a promising
biomarker.55 Recently, many AD clinical and research settings have applied Aβ PET
imaging, and an effort has been made to obtain FDA approval for the use of amyloid PET
tracers in the diagnosis of AD and other dementias.56 However, the challenge with PiB is
related to the stability of the 11C radioisotope due to its short half-life of only 20 minutes.
Recently, alternative Aβ tracers have been developed including (E)-4-(2-(6-(2-(2-(2[18F]-fluoroethoxy) ethoxy) ethoxy) pyridin-3-yl) vinyl) -N-methyl benzenamine
(Florbetapiror [18F]-AV-45) and Trans-4-(N-Methylamino)-4´-(2-[2-(2-[18F] fluoroethoxy) ethoxy] ethoxy) stilbene ([18F]-BAY94-9172)57 with a half-life of 110 minutes
making it more accessible to imaging sites.58 New tau PET tracers can also be used to aid
in diagnosis and monitoring of disease progression. Tau PET tracers have at least two
distinct forms; non-selective tau tracers that binds to both extracellular Aβ plaques and
intracellular neurofibrillary tangles, and selective tau PET tracers that are highly selective
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for tau over Aβ. For example, Barrio and colleagues developed and showed that 2-(1-(6[(2-[18F] fluoroethyl) (methyl) amino]-2-naphthyl) ethylidene) malononitrile ([¹⁵F]FDDNP), can bind to both intercellular neurofibrillary tangles and extracellular Aβ
plaques in AD subjects.59,60 While, 6-[(3-[¹⁵F] fluoro-2-hydroxy) propoxy]-2-(4dimethylaminophenyl) quinolone ([¹⁵F]-THK5105) and 6-[(3-[¹⁵F]fluoro-2-hydroxy)
propoxy]-2-(4-methylaminophenyl)

quinolone

([¹⁵F]-THK5117)

are
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F-labeled

arylquinoline derivative examples of selective tau PET tracers and have been shown to
have higher binding to tau over Aβ in AD.61,62 The combination of tau and Aβ PET
imaging will improve the specificity of diagnosis and potentially the early detection of
the pathology of AD. However, these tracers require more validation for use in research
and clinical centers. The development and assessment of new and better performing
tracers could provide insight into the causes and treatment of tauopathies such as AD.
The measurement of cerebral glucose metabolism rate with flurodeoxyglucose (18F)
positron emission tomography (FDG-PET) and perfusion in temporo-parietal cortex
using single photon emission tomography (SPECT) imaging have also contributed
substantially to understanding brain functional activity. FDG-PET was the most widely
used PET technique in AD, before the development of Aβ PET ligands. For over 20 years
in AD subjects, FDG-PET has been used to measure cerebral metabolic rates of glucose
(CMRglc) as an indicator of neuronal activity.56 Structural imaging using MRI can also
be used to measure region of interest (ROI) changes in tissue volume such as the
hippocampus.63-65
In summary, functional and structural biomarkers provide information about
underlying disease pathology, and the topography of neuronal damage and synaptic
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degeneration in AD. Such biomarkers include hippocampal volume, or other measures of
brain atrophy by MRI, FDG-PET imaging of glucose metabolism, and SPECT perfusion
imaging. These markers of neuronal injury may provide important measures of the brain
during the symptomatic disease stage. In contrast, molecular hallmarks directly reflect
AD neuropathology66 and can provide additional information during the asymptomatic
phase of the disease. Structural and functional biomarkers are more associated with
cognitive function over time than the molecular hallmarks.67,68 Jack and et. al.69 proposed
that the clinical disease stage (cognitively normal, mild cognitive impairment and
dementia) is associated with the amplitude of various biomarkers. For example, CSF Aβ
and amyloid PET measures are currently considered the earliest potential indicators of
disease followed by CSF tau and FDG PET, then structural MRI, prior to changes in
clinical function. Figure 1.4 illustrates one potential model of the cascade of current
biomarkers of Alzheimer’s disease. In addition to these well-established neuroimaging
biomarkers, diffusion tensor imaging (DTI), functional MRI (fMRI), resting state fMRI
(RS-fMRI), and MR spectroscopy (MRS) have all been used to further our understanding
of AD and investigated as potentially more sensitive indicators of disease. However, as of
yet, there are no definitive biomarkers of the disease, and as a result there continues to be
a need to improve MRI related measurements, as this non-invasive imaging modality is
highly cost effective and widely accessible. MRI will be discussed in more detail in the
following section.
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Figure 1.4 Proposed cascade of biomarkers in Alzheimer’s disease
One potential cascade of the biomarkers associated with Alzheimer’s disease in this figure from
Jack et. al.70 The earliest changes are expected to be Aβ accumulation detected in CSF and PET
imaging, followed by CSF tau and synaptic dysfunction measured using FDG-PET, brain atrophy
and neuronal loss measured using MRI, memory loss and clinical function measured by cognitive
assessments.[4]

1.5.1 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a non-invasive imaging modality without
ionizing radiation used to produce three-dimensional anatomical images (~1 mm3 voxel
size). The tissue in our brain is composed of approximately 80% water molecules, which
contains protons. The MRI scanner produces a strong magnetic field and causes the
protons within a sample to distribute between two different energy states (low energy and
high energy). This is known as Zeeman splitting. There is a slight excess of protons in
the low energy state inside the magnetic field of the MRI scanner. A radiofrequency
[4]

Adapted from The Lancet Neurology, 9 (2010), C. R. Jack, et. al., Hypothetical model
of dynamicbiomarkers of the Alzheimer's pathological cascade, 119-139, © 2016, with
permission from Elsevier
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pulse is then applied to the sample, causing an excitation of the sample whereby some
protons are elevated to the high-energy state and are brought into phase coherence. After
the pulse, protons return to their baseline (equilibrium) energy level distribution within
the magnetic field of the MRI. There are two processes that contribute to the relaxation of
the protons back to equilibrium. First, T1 relaxation is the process by which the protons
lose energy to the sample and the high energy spins return to the low energy state.
Second, T2 relaxation is the process that describes the loss of phase coherence of the
spins after the excitation pulse. The loss of energy and phase coherence of the sample is
recorded as spatially localized signals using a radiofrequency (RF) coil tuned to the
frequency of protons in the magnetic field. The use of magnetic field gradients to encode
spatial information in combination with signal excitation is used to produce detailed
anatomic images.
The relative signal intensities of tissues in MR image is determined by 1) the
radiofrequency pulse used, 2) the intrinsic T1 and T2 relaxation time constants of the
tissue, and 3) the proton density of the tissues. Therefore, depending on the scanning
protocols, the brain gray matter, white matter and CSF can be differentiated based on
voxel intensity. Proton density (PD), T1-weighted and T2-weighted methods are typically
used for structural imaging. Figure 1.5 shows the gray matter, white matter, and CSF in
T1-weighted and T2-weighted images. In T1-weighted MR images, the intensity
distributions of the tissues in the normal adult brain has the highest intensity in white
matter, medium intensity in gray matter, while CSF has the lowest intensity. Gray matter
contains more cell bodies including neurons and glial cells than white matter, which
primarily consists of nerve fibers (myelinated axons), along with supporting glial cells. In
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T1-wighted images, the CSF as well as dense bone and air become dark (void of signal).
Fat tissue like lipids in the myelinated white matter appears bright. Therefore, this
anatomical image can provide contrast between gray matter and white matter as well as
between subcortical gray matter and white matter. In addition, it offers good contrast
between neocortex and white matter. While in T2-weighted images, CSF appears bright
(high-intensity), while fat such as lipid in white matter shows dark (low-intensity). T2weighted images provide good contrast between CSF (high-intensity) and brain tissue
(low-intensity) and are more sensitive to white matter disease due to the hyper-intensity
of tissue with increased water content. Recently, brain volumetric measurements from T1weighted MR images of the brain including gray matter, hippocampus, amygdala, and the
brain ventricle have been investigated in subjects with AD and healthy subjects using
semi-automated or automated segmentation techniques.71-74 Hippocampus volume
reduction75-77 and enlargement of ventricle volume63 are the most common neuroimaging
biomarkers in subjects with MCI and AD.78 The use of such MRI biomarker could aid in
the diagnosis, treatment planning, and treatment monitoring of people with AD.
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Figure 1.5 Gray matter, white matter, and CSF in T1/T2 weighted images

Gray matter, white matter and CSF in T1-weighted and T2-weighted images are shown for one
healthy subject. Images are adopted from ADNI (Alzheimer Disease Neuroimaging Initiative)
database.

1.5.2 Positron Emission Tomography
Positron emission tomography (PET) is a radiotracer imaging technique with tracer
compounds labeled by positron-emitting radionuclides that are injected into the subject.
After injection of a tracer, the subject is placed into a PET scanner within the field of
view (FOV) of a number of detectors. The radionuclide in the radiotracer decays resulting
in positron emission. The released positron interacts with an electron and produces two
photons that are released in opposite directions (separated by 180 degrees). These
photons are detected and localized by the detector array surrounding the subject. These
events can be stored in arrays corresponding to projections through the subjectand
reconstructed to form an image using standard tomographic techniques.79,80 The resulting
images show the tracer distribution throughout the body and can be used to track
biochemical and physiological processes in the subject.
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In AD there are two radiotracers have been most commonly investigated.
18

Fluorodeoxyglucose provides functional information based on measuring cerebral

glucose metabolic rate (CMRglc) and is an indicator of neuronal activity in AD subjects.
Reductions of CMRglc may occur early in AD, are associated with disease progression,
and could be used as a predictor of histo-pathological diagnosis.56 Previous studies have
shown that the CMRglc is decreased in AD subjects, particularly in the medial temporal
lobe, posterior cingulate, and temporo-parietal areas.81-83 The accuracy of distinguishing
AD from healthy subjects was shown to be 98% with 99% sensitivity and 98% specificity
based on CMRglc abnormalities in several ROI including parietotemporal and posterior
cingulate cortices.84 In addition, subjects with MCI can be classified from healthy people
with 79% accuracy, 68% sensitivity and 100% specificity.85
Another more recent molecular PET imaging tracer is

11

C-Pittsburgh Compound B

(11C-PIB),86 which binds to amyloid plaques. PIB retention reveals the presence of
amyloid in brain regions of AD subjects. A previous study compared the PIB-PET
retention in several ROIs, but the highest accuracy of 96% to discriminate between AD
subjects and healthy subjects was found in the posterior cingulate, with 94% sensitivity
and 100% specificity. The accuracy of diagnostic classification between MCI and AD
groups was 70% with 94% sensitivity and 62% specificity using retention in the middle
frontal gyrus.87 Over the past five years, tau ligands have also been developed for PET
imaging and are now being intensively studied.88,89 One limitation of PET scans is that
the typical effective radiation dose of FDG is about 7 mSv and the effective radiation
dose with PET-CT is 5 to 18 mSv90 while the natural background radiation dose is 3
mSv. In addition, production of FDG requires a cyclotron and FDG has a short half-life

19
(110 min). Therefore, delivery from the manufacturer and completion of the scan must
occur very rapidly. However, a PET scan could aid and improve diagnostic accuracy and
therefore the potential benefits are often more important than the radiation risk.

1.5.3 Resting State Functional Magnetic Resonance Imaging
Functional magnetic resonance imaging (fMRI) is a non-invasive functional
neuroimaging technique that uses the MRI to infer brain activity using blood oxygen
level dependent (BOLD) contrast.

In particular, blood cells containing oxygenated

hemoglobin are diamagnetic and don’t distort the magnetic field, while blood cells
containing deoxygenated hemoglobin are paramagnetic and produce a localized magnetic
field distortion.

The signal intensity in BOLD images is related to the ratio of

oxygenated to de-oxygenated hemoglobin levels in the blood, which is also affected by
changes in local blood flow and volume. T2*-weighted imaging is typically the most
sensitive to changes in BOLD signal. When local brain activity increases, the local blood
flow increases to meet increased glucose demands. However typically there is an
oversupply of oxygenated blood for the required oxygen demands. Therefore, the relative
amount of de-oxygenated hemoglobin decreases and the intensity of the BOLD weighted
image increases. The spatial resolution of fMRI varies from 1 to 6 millimetres with a 1-5
second (between volumes) temporal resolution. While other techniques including
electroencephalography (EEG) or magnetoencephalography (MEG) have a higher
temporal resolution (ms), they suffer from poorer spatial resolution.
Spontaneous low frequency fluctuations (<0.1 HZ) in the BOLD signal have been the
subject of intense study in the last five years. Initial studies with an overt finger-tapping
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task and without performing an explicit task or thought (resting state) were performed by
Biswal et.al. in 1995.91 Biswal and colleagues compared the functional connectivity
derived from a finger-tapping task in sensorimotor cortex to the same subjects during a
resting state. They showed low frequency signal in the resting brain was highly correlated
with the task activation map. Functional connectivity is expressed as the association
between the neuronal activation of anatomically separated brain regions.92 Analysis of
resting state fMRI data reveals brain networks. The organized functional architecture can
be categorized into two groups, 1) model dependent and 2) data driven methods. In the
model based method, some anatomical/structural ROIs that are called seeds are selected.
Correlation metrics are used to make a functional connectivity map by determining
whether other regions are functionally related and connected to these seed regions.93
These metrics include cross correlation analysis94 and coherence analysis.95 The data
driven methods are divided into two categories; decomposition methods including
independent component analysis (ICA),96 principle component analysis (PCA),97,98 and
clustering algorithms.99
The limitation of seed based methods is that hypothesis driven seeds must be
selected. Independent component analysis or clustering methods are limited by the
definition of the optimal number of independent components (IC) or clusters. However,
some metrics are used to predict the "goodness-of-fit" to determine the optimal number
of (IC) or clusters. Generally, a low number of components (20-30) are sufficient for
identifying networks and avoiding the redundancy that occurs with increasing numbers of
components.100
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Previous studies100 have shown that several networks of functionally related brain
regions are active during the resting state, and are called resting state networks (RSNs).
The ICA method can be used to detect these RSNs. The ten most common RSNs are: 1)
left executive control network, 2) right executive control network, 3) auditory network, 4)
visual medial network, 5) visual occipital network, 6) visual lateral network, 7) salience
network, 8) default mode network, 9) sensorimotor network and the 10) cerebellar
network. The three visual networks are associated with cognition–language (orthography)
and cognition–space functions. The executive network includes several medial frontal
regions, the anterior cingulate and the paracingulate, and is associated with several
cognition, action, emotion, and perception tasks. The cerebellar network includes the
cerebellum and plays role in motor control and some cognitive domains. The auditory
network covers the superior temporal cortices and is associated with speech processing,
language processing, and perception–audition functions. The salience network includes
frontoparietal areas and is associated with cognition and language paradigms. The
sensorimotor network mainly consists of the primary motor area and somatosensory
cortex and has functions in bimanual action tasks and the control of sequences of
movements. The default mode network mostly consists of medial, anterior, lateral lobes,
medial prefrontal cortex, and the posterior cingulate cortex (PCC). It is associated with
emotion, episodic memory, thoughts and judgments.100 Previous studies have identified
decreased activity in the default mode network mainly in the hippocampus in AD
compared to healthy elderly groups and have suggested that it could be used as a clinical
marker of AD.101,102 A cross-sectional study showed that the activity of the default mode
network may actually increase at the early stages of MCI but is decreased in the later
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stages of MCI, similar to the decrease shown in AD patients.103 These changes could be
related to underlying structural changes that consequently affect the communication
between structurally connected regions and could directly relate to the common
symptoms associated with MCI, AD and their various stages of severity.
In summary, neuroimaging is a promising method for the early detection of AD.
There are multiple brain imaging techniques that can be used to detect abnormalities or
changes in the brain, including PET, MRI, and RS-fMRI scans. These methods in
combination with advanced registration, segmentation, and the use of classifiers could
significantly increase the sensitivity and specificity of AD detection. The studies detailed
in this thesis illustrate the basic theory of registration, segmentation and the use of
classifiers that can be applied to brain imaging. Specific details of these methods will be
provided in the following sections.
1.6 Registration
Registration is the process of alignment a target (moving) image MX with a source
(fixed) image FX by finding the spatial mapping between the two images. The registration
can be applied on image feature space including pixel (voxel) intensities from the entire
image or some points (landmarks) within the images.104 Registration algorithms involve
several components including geometric transformation, similarity metrics, and
optimization processes. The transform component TX represents the spatial mapping of
points from the fixed image space to points in the moving image space. A similarity
metric component S (FX, MX ∘ TX) provides a measure of the goodness that the fixed
image is aligned to the transformed moving image. An optimizer component is an
algorithm used to find the transformation parameters that maximize the matching
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criterion. Registration methods can be classified into rigid (only rotation and translation),
affine (rotation, translation, scaling, and shearing), and non-rigid registration with more
degrees of freedom (parameters) based on the dimensionality of the transformation
matrix.105 Often, rigid or affine registration methods are used as a pre-processing step
before non-rigid registration to align two images.
The similarity metric evaluates the goodness value of an objective function and is
passed to the optimizer algorithm. Therefore selection of an appropriate metric is highly
dependent on the registration application. There are different similarity metrics including
mean squared error (MSE), normalized mean score error (NMSE), normalized correlation
coefficient (NCC), and the normalized mutual information (NMI). The mean square
error105 (MSE) is the simplest and most straightforward similarity metric and is defined
by Equation 1.1 below.
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MSE 𝐹, 𝑀 =      !
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!

𝐹 𝑥, 𝑦 − 𝑀(𝑥, 𝑦)

!

[1.1]

F (x, y), and M (x, y) are the intensities of pixel in the fixed image (F) and moving
image (M) at location x, y. The optimal value of the metric is zero and poor registrations
produce large values of the metric. This metric relies on the assumption that the intensity
representing the same homologous point is the same in both images and therefore is only
suited for two images with the same intensity distributions, i.e. for images from the same
modality. In order to overcome this problem, one may use a normalized version of the
metric as shown in Equation [1.2].
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24
F (x, y), and M (x, y) are the intensities of the pixel in the fixed image (F) and
moving image (M) at location x, y. 𝐹 and 𝑀 are the mean intensity value in the fixed and
𝐹−𝐹

moving images.

!

and 𝑀 − 𝑀

!

are the L2-normfor the intensity scale

normalization.L2-norm is also known as the Euclidean norm and L2-norm of vector
X=(x1, x2,…, xn) is given by Equation [1.3]:
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Another normalized metric is the normalized correlation coefficient106 (NCC) shown
in Equation [1.4].
𝐍CC 𝐹, 𝑀 =   
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𝜎! and  𝜎! are the standard deviations of the intensities in the fixed and moving images
and have an ideal value of 1. This metric computes the correlation between pixels in the
fixed image and pixels in the moving image. The correlation is normalized by the square
rooted autocorrelations of both the fixed and moving images. The metric is invariant to
linear differences between intensity distributions and is therefore appropriate for a single
modal registration and for multi-modality registration.
Equation [1.5] provides the definition of the normalized mutual information (NMI)107
function:
NMI 𝐹, 𝑀 =   

𝐻 𝐹 + 𝐻(𝑀)
                                                                                                                                                                                                      [1.5]
𝐻(𝐹, 𝑀)

The Mutual Information (MI) measure computes the mutual information between
two images and is more general. MI is a measure of how much information one random
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variable (image intensity in one image) tells about another random variable (image
intensity in the other image). This corresponds to measuring the dependency of the
probability distribution function (PDF) of the intensities of the fixed and moving images
without having to specify the actual form of the dependency. Normalized Mutual
Information is appropriate for multi-modality registration.

1.6.1 Registration Validation
To evaluate the effectiveness of a registration method, an anatomically homologous
pair of landmarks is identified and target registration error (TRE)108 is measured and
denoted by Equation [1.6].
                                                    TRE =   

𝑇 𝑥! − 𝑥!

!

!

+ 𝑇 𝑦! − 𝑦!                                                                                           [1.6]      

This metric measures the Euclidean distance between the location of the transformed
moving landmark and its homologous fixed landmark. A perfect registration has an ideal
value of zero. In practice, we manually identify multiple anatomically homologous
landmark pairs, and calculate TRE for each pair. The final TRE value is measured by
taking their mean.
In practice, three measures of volume overlap and two measures of overlap error can
be used to evaluate the overlap of registered images.
The first volume overlap measurement is called the target overlap (TO).109 This
measure computes the intersection between two regions r in a transformed moving image
(S) and a fixed image (F) divided by the volume of the region in the fixed image denoted
by Equation [1.7].
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𝑇𝑂 =

𝑆! ∩ 𝑇!
                                                                                                                                                                                                                                                          [1.7]
𝑇!

The second volume overlap measurement is called the mean overlap (MO).109 It is
the intersection divided by the mean volume of the two or multiple regions and is denoted
by Equation [1.8].
𝑀𝑜 = 2

∑! 𝑆! ∩ 𝑇!
                                                                                                                                                                                                                          [1.8]
∑! 𝑆! + 𝑇!

The third volume overlap measurement is called the union overlap (UO).109 It is the
intersection divided by the union of the two or multiple regions as denoted by Equation
[1.9].
𝑈𝑂 =

∑! 𝑆! ∩ 𝑇!
                                                                                                                                                                                                                                              [1.9]
∑! 𝑆! ∪ 𝑇!

The false negative error109 is a measurement of how much of the region is incorrectly
labeled. It is computed as the volume of a fixed region outside the corresponding
transformed moving region divided by the volume of the fixed region and denoted by
Equation [1.10].
𝐹𝑁 =

∑! 𝑇! \𝑆!
                                                                                                                                                                                                                                                [1.10]
∑! 𝑇!

Where 𝑇! \𝑆! shows the set of voxels in the fixed region but not in the transformed
moving region.
The false positive error109 is the measurement of how much of the volume outside a
region is incorrectly labeled as inside region. It is computed as the volume of a
transformed moving region outside the corresponding fixed region divided by the volume
of the transformed moving region and is denoted by Equation [1.11].

27

𝐹𝑃 =

∑! 𝑆! \𝑇!
                                                                                                                                                                                                                                                [1.11]
∑! 𝑆!

1.7 Segmentation
Image segmentation is the process of the identification of image pixels within regions
or categories that correspond to different objects or parts of an object.110 In 2D/3D/4D
medical images, these segments often relate to different tissues, organs, or other relevant
structures. Low contrast, noise, and other imaging artefacts can make medical image
segmentation difficult. Imaging modalities including MRI generate three dimensional
image volumes with high resolution and a large number of image slices making manual
examination extremely time consuming. However, automated or semi-automated image
segmentation techniques can overcome this problem and have been adapted specifically
for medical image analysis. In addition, image segmentation methods are required in
clinical applications to assist the observer in generating quantitative measurements and
may provide support in diagnosis and response to treatment planning. Segmentation
algorithms can be divided into low level and model based categories. Low level includes
boundary-based, region-based and pixel-based segmentation methods. Model based
methods incorporate high-level image features including boundary smoothness, shape,
and appearance. Edge based or boundary methods are the most common approaches to
find discontinuities in gray level images using edge detectors. Edges are the boundary
between two regions. All the edge detection operators are grouped into first order and
second order derivatives.
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1.7.1 Region-Based Method
Region-based techniques partition an image into regions. Region growing is the
simplest region-based method,111 which groups pixels or sub regions into larger regions
based on predefined criteria. A set of seeds (pixels) is selected in the image and a
similarity criterion (e.g. intensity, color, texture) is defined. Then the region grows when
the neighbouring pixels have a similar value and the region growing stops when no more
pixels meet the criteria. Region growing algorithms differ in the criteria used to
determine whether a pixel is included in the region or not. A major limitation of this
technique is that regions of interest can have very similar intensity. If two anatomical
structures share a boundary and the same intensity distribution, the growing region will
’leak’ into undesirable regions. If the regions have uniform intensities and clear
boundaries, region-growing methods can be quick and effective for many segmentation
problems.

1.7.2 Pixel-Based Method
Thresholding is the simplest method for pixel-base segmentation112 and is used to
identify pixel values in an Image I (x, y) based on specifying one or more values as the
threshold value. This operation transforms an image to a binary map by changing the
pixel values according to the threshold value. Upper and lower thresholds are two
intensity values defined by user. If the pixel value belongs to the defined range (lower,
upper) the intensity of the output pixel is unchanged, otherwise the intensity is changed to
zero. The major disadvantage of this method is that it is not appropriate for complicated
images, but if there is a good contrast between regions, it performs well.
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1.7.3 Level Set
The level set method implicitly represents a contour or surface by defining a level set
function that is usually defined on the same domain as the image. This method was
proposed by Osher and Sethian.113 The level set114-116 is considered as the set of points
that have the same function value. For example a contour can be embedded as a zero
level set of the higher-dimensional level set function Ψ (x, y) by Equation [1.12]:
𝜓   𝑥, 𝑦 = 0                                                                                                                                                                                                                                                                [1.12]
and every point of the region Ω is determined by the sign of the level set function Ψ
by Equations [1.13, 1.14]:
𝜓   𝑥, 𝑦 > 0,                   𝑥, 𝑦 ∈   Ω                                                                                                                                                                                                    [1.13]
𝜓   𝑥, 𝑦 < 0,                   𝑥, 𝑦 ∉   Ω                                                                                                                                                                                                    [1.14]
The contour at the zero level set can be evolved by updating the level set function at
fixed coordinates through time by Equation [1.15]
𝜕𝜓
= 𝑉 ∇!                                                                                                                                                                                                                                                                 [1.15]
𝜕𝑡
where V is a speed function to evolve the contour throughout the image domain. The
main advantage of the level set method is that a complex shape and topological changes
including merging and splitting can be modeled.

1.8 Classifiers
Machine learning (ML) is a process of developing algorithms that uses input data to
accomplish a desired task. These algorithms are trained through experience and therefore
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their performance improves to obtain a particular outcome. This training is the learning
part of machine learning. The selection and weighting of input data and the algorithm’s
parameters that are modified through iterative optimization can help to improve the
training portion. To achieve this goal, a dataset can be divided into training and testing
sets; the training set is used to teach the algorithm to accomplish a goal and the testing set
is used to validate the acceptability of the identified goal. Machine learning can be
divided into supervised, unsupervised, and semi-supervised learning based on the nature
of data labeling. The goal of supervised learning is to learn how to estimate an unknown
data (input, output) mapping from the training set (input, output), where the output is
labeled (e.g. an artificial neural network, or a support vector machine). In the
unsupervised leaning, the input data is given to the learning system to infer a function to
describe hidden patterns in the data. The inputs that are used in this leaning are unlabeled
(e.g. principle component analysis and clustering methods). Semi-supervised learning is a
type of supervised learning and uses a combination of both labeled data and unlabeled
data where the labeled data is used to estimate the unlabeled data. Another category of
machine learning is reinforcement learning that is presented with inputs, actions, and
rewards. Its goal is to learn how to find a sequence of actions that may maximize the
reward (e.g. robots, chess programs).117 Figure 1.6 summarizes of these types of machine
learning.

31

Figure 1.6 Different categories of machine learning
In supervised learning, labeled examples are available, while in unsupervised learning, labeled
examples are not available. Semi-supervised learning combines both labeled and unlabeled
examples to generate an appropriate function.

Supervised learning is the most commonly used method in neuroimaging. The input
data is determined by a number of image features like the number of voxels, mean
intensity, standard deviation of intensity, and volumes of ROIs. The output data is the
subject’s class or label (ground truth). The labels are often binary, for example patient or
control, or improver or decliner. Here, the objective of ML methods in neuroimaging is to
use image features to predict the subject’s label. These ML methods are also called
classifiers. ML algorithms (classifiers) have been used previously to identify subjects
with Alzheimer disease from healthy subjects using MRI biomarkers.118 For example, in
one study, the classification accuracy was 76% between AD and healthy subjects and
72% between MCI and healthy subjects using training data from 137 AD, 76 MCI and
162 healthy subjects.118
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1.8.1 Support Vector Machine
The support vector machine119,120 (SVM) is one of the most powerful tools for
supervised learning and is used in classification and regression problems. SVM
algorithms are well known for their strong statistical theory, generalizable performance,
and ability to handle highly dimensional data.121,122 The training data can be characterized
as

𝑥! , 𝑦! … 𝑥! , 𝑦!

where 𝑥!   , 𝑖𝜖  𝑛  are multi dimensional instances (observations), 𝑦!

are the labels of those instances, and n is the number of instances in the training set. In
neuroimaging 𝑥!   is the feature vector characterized from each image, 𝑦! ∈    (+1, −1) is a
label that is assigned to each subject and n is the number of subjects in the training set.
SVM is a classification method to find the optimal separating hyperplane between the
positive examples (labeled +1) and the negative examples (labeled -1) with the largest
margin. The margin is defined as the distance between the hyperplane and the training
examples (positive and negative examples) that are closest to the hyperplane. Figure 1.7
shows this hyperplane between positive samples (red circles) and negative samples
(green squares).

Figure 1.7 Separation line between two classes using a support vector machine
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Therefore, the hyperplane can be defined by the normal vector 𝑊 and intercept 𝑏 by
Equation [1.16]:
𝑊 ! 𝑥 + 𝑏 = 0                                                                                                                                                                                                                                                            [1.16]
Here, the labels 𝑦! ∈    +1, −1 corresponding to the examples 𝑥!   , 𝑖𝜖  𝑛 in the training
set are replaced by +1, -1 according to the following rule by Equation [1.17]:
𝑦! =

1             ∶    𝑊 ! 𝑥! + 𝑏 > +1
                                                                                                                                                                                              [1.17]
−1       ∶    𝑊 ! 𝑥! + 𝑏 < +1

These two constraints can be combined into the following by Equation [1.18]:
𝑦! 𝑊 ! 𝑥! + 𝑏 ≥ 1                                      ∀!                                                                                                                                                                                           [1.18]
The margin can be easily computed as the distance between the example point x and
hyperplane based on geometry as follows by Equation [1.19]:
Margin =   

𝑏 + 𝑊!𝑥
1
=
                                                                                                                                                                                            [1.19]
𝑊
𝑊

𝑊 is the Euclidean norm of W. The problem of maximizing the margin is not easy
because the vector norm includes a square root. Therefore, it is equivalent to minimizing
the problem by Equation [1.20]:
min  𝐿 𝑊 = 𝑊

!

                                subject  to                                𝑦! 𝑊 ! 𝑥! + 𝑏 ≥ 1      ∀!                                             [1.20]

This formulation is known as the primal form and is solved using the Lagrangian
formulation by Equation [1.21]:
!

min 𝐿 𝑊, 𝑏, 𝛼 =    𝑊
!,!

!

−

!

𝛼! 𝑦! 𝑥! 𝑊 + 𝑏 +
!!!

𝛼!                                                                                               [1.21]
!!!

The non-zero Lagrange multipliers (𝛼! > 0) are called support vectors and they
correspond to example points that lie directly on the optimal margin.

34
When the data is not linearly separable using kernels can enable the use of support
vector machines. Kernel methods can be used in the Lagrangian expression of the SVM
optimization problem by incorporating a kernel function. With this approach, the data can
be mapped to a higher dimensional space where the data is linearly separable. There are a
number of kernel types including linear, polynomial, Gaussian, and sigmoidal. In a real
application, kernel methods do not guarantee optimal results and may lead to over-fitting.
To overcome this limitation, regularization or a soft margin can be used to find a
hyperplane by relaxing the constraints in the optimization problem. Typically the
regularization parameter C and another parameter γ (when using a Gaussian kernel) that
control the mapping of the original data to the higher dimensional space require
optimization.123-125 The advantages of the SVM are that it is an accurate classifier with
little over-fitting and is robust to noise. The disadvantage of the SVM is that its
performance is highly dependent on parameter tuning and it is only a binary classifier.126
Cross validation is a statistical type of validation learning algorithm that works by
dividing data into two groups: (1) training data is used to learn a model and (2) test data
is used to evaluate the model.127 Cross validation methods estimate the performance of a
learned model using the test data.128 They can be used for comparison between two or
more algorithms to find the best one. There are a number of ways to achieve this goal.
One of the most widely used when the sample size of the data is small is the leave-oneout cross validation (LOOCV).129,130 Here, in each iteration, all the data (training data)
except one single datum (test datum) is used to train the model and the model is tested on
that test datum. This process is repeated so that each sample in the data is used as the test
datum. LOOCV is known to suffer from over-fitting and over estimates the performance
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of models. Another popular method is k-fold cross validation131,132 which divides the data
set into k folds and the model is trained using k-1 folds. The model is validated using the
k-th fold (test data). This process is repeated k times.
1.9 Validation of classification performance
Accuracy, sensitivity, and specificity are statistical measurements to evaluate the
performance of a binary classification such as SVM. For example with two classes (1 and
2), class 1 refers to a group of patients (“positive” based on the clinical conditions) and
class 2 corresponds to a group of controls (“negative” based on the clinical condition).
The four components are typically characterized are:
1. True positive (TP): the number of subjects who have the positive condition
(patient) correctly identify as class 1 (patient)
2. False positive (FP): the number of subjects who have the negative condition
(controls) incorrectly identify as class 1 (patient)
3. True Negative (TN): the number of subjects who have the negative condition
(controls) correctly identify as class 2 (controls)
4. False negative (FN): the number of subjects who have the positive condition
(patient) incorrectly identify as class 2 (controls)

Therefore, the sensitivity, specificity, and accuracy can be defined using Equations [1.221.24] below:
Sensitivity =   
Specificity =   

𝑇𝑃
  ×  100                                                                                                                                                                                        [1.22]  
𝑇𝑃 + 𝐹𝑁

𝑇𝑁
  ×  100                                                                                                                                                                                            [1.23]
𝑇𝑁 + 𝐹𝑃
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Accuracy =   

𝑇𝑃 + 𝐹𝑁
  ×  100                                                                                                                                                  [1.24]
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁

Sensitivity is the proportion of patients that are correctly identified; specificity is the
proportion of healthy subjects that are correctly identified. Accuracy is the percentage of
correct classifications. The error rate= 1- accuracy, is the percentage of incorrectly
classified subjects.

1.10 Validation of segmentation techniques
One of the most challenging issues in a clinical setting is the comparison of different
segmentation methods. Initial evaluation is often accomplished visually by overlaying
contours or boundaries derived from each segmentation methods on the medical images.
To overcome drawbacks intrinsic to visual perspective, a quantitative validation is
preferable and most approaches use a gold standard to compare different methods. A
ground truth method can be considered a benchmark to test against, however actual
ground truth knowledge is often not available. A physical or digital phantom can be
constructed for which the ground truth is known, but a problem is associated with this
approach. Composing a physical phantom is challenging because it is difficult to
reproduce the normal and pathological anatomical variability observed in clinical data.
Gold standards typically rely more on contours that are manually defined by clinical
experts in the medical images of interest. This manual segmentation is performed by
using anatomical landmarks to produce label maps (also know as a mask). Therefore, to
assess the performance of a segmentation technique, some statistics measurements are
used to compare a newly developed method to an existing method or gold standard. For
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this purpose, some metrics are described below and can be divided into three groups
including spatial overlap, distance and volumetric measures.

1.10.1 Region-Based Metric
Region based metrics compute the overlap between regions. This metric is used to
measure the portion of spatial overlap between two mask images that were generated by
the segmentation method (𝑟𝑒𝑔𝑖𝑜𝑛! ) and a gold standard (𝑟𝑒𝑔𝑖𝑜𝑛! ).
The Dice similarity coefficient (DSC)133 is defined by Equation [1.25]:
DSC =   

2 𝑟𝑒𝑔𝑖𝑜𝑛! ∩ 𝑟𝑒𝑔𝑖𝑜𝑛!
                                                                                                                                                                                          [1.25]
𝑟𝑒𝑔𝑖𝑜𝑛! + 𝑟𝑒𝑔𝑖𝑜𝑛!

The Jaccard index (JI)134 is characterized as a proportion of the intersection between
two regions over their union by Equation [1.26]:
JI =

𝑟𝑒𝑔𝑖𝑜𝑛! ∩ 𝑟𝑒𝑔𝑖𝑜𝑛!
                                                                                                                                                                                                      [1.26]
𝑟𝑒𝑔𝑖𝑜𝑛! ∪ 𝑟𝑒𝑔𝑖𝑜𝑛!

The Jaccard index is always larger than the Dice index but both of these metrics
measure the same aspects and do not provide additional information.

1.10.2 Distance-based metric
This metric can measured the distance between points in 𝑟𝑒𝑔𝑖𝑜𝑛! and 𝑟𝑒𝑔𝑖𝑜𝑛! .
Mean absolute distance (MAD)135,136 is defined by Equation [1.27]:
1
MAD =   
𝑁

!

𝑑(𝑃! , 𝑃! )                                                                                                                                                                                                                 [1.27]
!!!

where 𝑃! is the set of points in 𝑟𝑒𝑔𝑖𝑜𝑛! and 𝑃! is the set of points in 𝑟𝑒𝑔𝑖𝑜𝑛! . N is
the number of points and this distance is based on the Euclidean distance in mm.
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The Hausdorff distance137 is the measurement of the error between two surfaces. It
computes the maximum distance of a set point in region A to the nearest point of region
B. Therefore, this distance can be used to determine the degree of similarity between two
regions that are superimposed on one another and denoted by Equation [1.28].
ℎ 𝐴, 𝐵 = max min 𝑑 𝑎, 𝑏
!  ∈!

!  ∈!

                                                                                                                                                                                          [1.28]

1.10.3 Volume based metric
The percentage volume difference (VD) is defined as the ratio of the absolute
difference between the segmented volume 𝑉! and the gold standard volume 𝑉! by
Equation [1.29]:
VD =   

𝑉! − 𝑉!
  ×100                                                                                                                                                                                                                          [1.29]
𝑉!

1.10.4 Variability
Human expert operators have often been used for gold standard segmentations and
many segmentation methods use initialization or manual intervention. These are
associated with high intra-observer and inter-observer variability. Therefore, the
variability can be measured by the intra-class correlation coefficient (ICC),138,139 BlandAltman plot,140 and the coefficient of variation.141 These metrics are used to describe the
effect of accuracy between and within operators and segmentation methods.
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1.11 Thesis Overview
The preclinical or pre-symptomatic stage of AD is associated with pathological
changes that begin 10-15 years before synaptic or neuronal loss result in cognitive
decline and dementia. New disease modifying drugs are urgently needed to intervene at
the pre-symptomatic stage in the disease process to prevent brain damage and subsequent
cognitive decline and dementia. Currently, AD is diagnosed base on the results of a
clinical examination and cognitive testing. But such a diagnosis occurs too late in the
disease process and is subject to error because a definitive biomarker does not exist.142 A
diagnosis based on clinical examination and cognitive testing cannot detect presymptomatic AD and cannot accurately measure the rate of disease progression. There is
an urgent need to develop biomarkers that can definitively identify early Alzheimer’s
disease so that new potentially disease modifying drugs can be tested in the appropriate
people.
It is challenging to develop biomarkers for presymptomatic AD because early
changes in the brain are subtle. The ideal biomarker should reveal AD pathology, be
reliable, be easy to measure, and be relatively inexpensive.143 Imaging methods including
anatomical MRI, PET, and functional MRI, which can assess regional/global structural
and functional impairment have the potential, particularly when used in combination, to
identify pathological changes associated with AD.
The overall objective of this thesis is to develop and test novel structural and
functional biomarkers of Alzheimer’s disease to improve AD diagnosis and treatment
monitoring.

Chapter 1 provides the necessary introductory material including an

overview of AD, MCI, the neuropathology of AD, the clinical diagnosis of AD, a review
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of current biomarkers, and background related to image registration and segmentation
theories. The thesis contains three independent chapters or studies:
Chapter 2 describes a new approach to the segmentation of the medial temporal
lobe (mainly hippocampus) from T1-weighted images in healthy, MCI and AD subjects
taking part in a longitudinal natural history study (2 years follow-up). The goal of this
work was to develop a reliable, and fully automated approach to quantify MTL atrophy
using MRI. The novel segmentation approach presented here combined a multiple atlasbased registration method to define the tissue region of interest, a level set algorithm to
refine the shape of the medial temporal lobe, and registration of baseline images to follow
up images to increase measurement precision. We hypothesized that the change in MTL
(ΔMTL) volume would be robustly quantified by this fully automated segmentation
method, and would be a sensitive marker of AD progression.
Chapter 3 describes and provides a cross sectional comparison of a new
biomarker of brain activity derived from resting state fMRI in healthy and AD subjects.
We also examine the association of this new metric to hypometabolism measured by
FDG-PET in the same cohort of subjects. Here, we defined a novel metric of brain
activity based on a first-order texture feature defined as the standard deviation of the
magnitude of the BOLD fluctuation. The purpose of this study was to determine whether
this new metric could be used to accurately differentiate healthy individuals from people
with mild Alzheimer disease. The hypothesis was that the fluctuation of the magnitude
of the BOLD signal as a function of time is related to neuronal activity and therefore will
also correlate with FDG-PET measures of glucose metabolism. The goal was to
demonstrate the efficacy of this new biomarker of Alzheimer’s disease based on the

41
fluctuation of the magnitude of the RS-fMRI signal.
Chapter 4 closely examines a group of subjects with MCI to determine whether gait
and cognitive measures can predict or are associated with medial temporal lobe atrophy
incorporating principle component analysis (PCA) and the SVM classifier.

Medial

temporal lobe atrophy over 18 months was evaluated using the novel method developed
in Chapter 2. The purpose of this study was to determine which combination of
biomarkers could best predict hippocampal atrophy over 18 months in people with MCI.
We hypothesized that the combination neuropsychological and gait measurements would
provide the best predictors of hippocampal atrophy.
Finally, in Chapter 5, we provide a summary of the findings of the thesis, a
discussion of the limitations of the work, and suggestions for future development.
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CHAPTER 2: Automated Algorithm to Measure Changes in
Medial Temporal Lobe Volume in Alzheimer Disease
The work presented in this chapter has been previously published in Journal of
Neuroscience Methods as indicated below, and is reproduced here with permission.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie and
Robert Bartha.
“Automated Algorithm to Measure Changes in Medial Temporal Lobe Volume in
Alzheimer Disease” J Neurosci Methods. 2014 Apr 30; 227: 35-46

2.1 Introduction
Alzheimer disease (AD) is the most common form of neurodegenerative dementia1
and progressively causes metabolic and structural changes in the brain that lead to
symptoms of cognitive decline. In 2006, approximately 14.7% of people over the age of
85 years were living with AD worldwide. By 2050, the worldwide prevalence of AD is
projected to quadruple compared to 2006 levels.2 The current diagnosis of AD is made
clinically incorporating neuropsychological and neuroimaging assessments. The clinical
progression of AD can be measured by cognitive assessments, most commonly the MiniMental-State Examination3 (MMSE), the Alzheimer Disease Assessment Scale-cognitive
subscale (ADAS-cog)4 and more recently the Montreal Cognitive Assessment (MoCA).5
However, these assessments have only moderate sensitivity to disease progression,4,6
particularly in the early stages of the disease. Therefore, numerous non-invasive imaging
techniques7-9 are being developed as potential quantitative biomarkers for the detection
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and monitoring of small structural,10,11 metabolic,12-15 and functional16 changes during the
early stages of the disease. In addition, the development of amyloid imaging techniques
using positron emission tomography (PET) now provides the ability to measure fibrillar
amyloid accumulation in the brain.17-19 These imaging tools could increase diagnostic
accuracy and allow monitoring of disease progression and response to treatment.10,20,21
Magnetic resonance imaging (MRI) is used to visualize anatomical changes in the
brain with high resolution and is therefore considered the preferred neuroimaging method
for early detection of AD.22 Progression of AD23-26 is often associated with increased
ventricle volume10 or atrophy of the medial temporal lobe (MTL) including the
hippocampus.23-25,27 Although the hippocampus is considered one of the first brain
structures affected by AD, accurate quantification of hippocampal atrophy is difficult
because the structure has an inhomogeneous texture with poorly defined boundaries.
Manual segmentation of the hippocampus on MRI is the gold standard

28

but is time-

consuming, subjective, and has high variability.29 In fact, only recently have attempts
been made to standardize the definition of the hippocampus for volumetric
measurements.30
Several studies have proposed atlas-based segmentation techniques to find the
optimal mappings between brain MRI and an atlas image using landmarks31-33 or
intensities.34-39 In addition, van der Lijn et. al.40 combined atlas-based segmentation with
graph cuts41,42 to define the hippocampus. Incorporating corresponding landmarks can
also help to compute geometric transformations rather than relying on intensity-based
registration. For example, an atlas-based registration method was applied by Wang et.
al.43 to segment the hippocampus; however, this method required the manual placement
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of a large number of landmarks in each scan. More recently, atlas-based registration has
been proposed for the detection of pathological changes in addition to the segmentation
of structures.44 Registration is treated as an optimization problem to find the spatial
mapping between two images. For example, to segment the hippocampus and amygdala
in images obtained from the ADNI dataset, Chupin et. al.37 registered images to a
probabilistic atlas with image deformation performed by minimization of an energy
function.45In general, providing an accurate segmentation of a structure using atlas-based
registration is important; however, the accuracy of the segmentation is heavily dependent
on the atlas. A single atlas cannot represent a whole population, particularly in datasets
with large variation and may lead to biased results. Therefore, the performance of atlasbased segmentation methods can often be improved using multi-atlas propagation.46-48
A number of other methods have also been developed and applied to the
segmentation of the hippocampus. Barnes et. al.49 developed a semi-automated
segmentation method to measure hippocampal volume changes by calculating the
boundary shift integral (BSI)50 in longitudinal MR images. Rusinek et. al.51 applied the
BSI to calculate the rate of MTL atrophy. Wolz et. al.39 combined a multi-atlas
registration with an intensity refinement model40 to segment the hippocampus. This
learning embedding for atlas propagation (LEAP) method was demonstrated by using
images obtained from the ADNI database.39 Coupe et. al.38 proposed a novel patch-based
method for hippocampus and ventricle segmentation that incorporated nonlocal means
label fusion.52 Fischl et. al.53,54 have also proposed an automated tool (FreeSurfer) for
segmentation of 37 neuroanatomical structures in the brain on MRI that includes 18
labels of subcortical structures. In this approach, a probabilistic atlas image is generated
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from a training set of 41 manually labeled brains. For each image to be segmented, the
probability that a pixel belongs to a specific structure (label class) is computed.
Preprocessing steps included an affine registration to Talairach space, intensity
normalization, skull stripping, and non-linear alignment to the Talairach atlas.53,54 An
initial segmentation is generated by assigning each pixel to the class for which the
probability is greatest. Given this segmentation, a neighborhood function is used to
recompute the class probabilities. The data set is then resegmented based on this new set
of class probabilities. This process is repeated until the segmentation does not change.
FreeSurfer is a fully automated segmentation pipeline.53,54 Similarly, Shen et. al.55 used a
surface model for segmentation of the hippocampus. This model integrated rigid
geometric alignment with shape variation as prior knowledge, but required manual
placement of landmarks on the boundaries. The prior knowledge increased the accuracy
of the boundaries and maintained the appropriate hippocampus shape, but manual
placement of points within an individual MR image was needed.
Existing methods of hippocampal segmentation mostly require manual intervention
at some point in the measurement to achieve accurate results.32,43,56 However, in applying
such methods to the monitoring of Alzheimer’s disease progression, we postulate that
segmentation accuracy is less important than sensitivity to change. Automation may be a
more highly desirable feature because it increases reproducibility and aids in analyzing
large datasets in a timely manner. Automated measurements of large volumes such as
frontal, parietal, temporal, and occipital lobes as well as cerebellum have been
successfully demonstrated by Andreasen et. al.57 In addition, subcortical structures such
as the thalamus, caudate nucleus, putamen and globus pallidus have also been measured58
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using deformable shape models based on automated or semi automated image
segmentation algorithms.59 By formulating a shape-intensity model in terms of a level set
function60 it is possible to segment images with poor contrast and missing boundaries.
Level sets are a type of geometric deformable model.61 Intensity-based techniques are
difficult to apply to the segmentation of the hippocampus because signal intensity varies
and boundaries are ill-defined. Deformable models can be used to extract boundaries
from objects with low contrast and indistinct edges. In this study, a geometric deformable
model (level set algorithm)62 was chosen that couldautomatically handle multiple objects
or an object with unknown topology and sharp corners. The Fast Marching segmentation
method is a type of level set method that can follow objects with topology changes when
an object splits in two, develops holes, or the reverse of these operations. This method
may offer an advantage when segmenting structures with low contrast boundaries such as
the hippocampus.
Therefore, the goal of the present work was to develop a robust, reliable, and fully
automated approach to quantify MTL atrophy using MRI. The novel segmentation
approach presented here combined a multiple atlas-based registration method to define
the tissue region of interest, a level set algorithm to refine the shape of the medial
temporal lobe, and registration of baseline images to follow up images to increase
measurement precision. The method was tested by comparing atrophy between a group of
normal elderly controls (NEC), subjects with mild cognitive impairment (MCI), and
subjects with AD. We hypothesized that the change in MTL (ΔMTL) volume would be
robustly quantified by this fully automated segmentation method, and would be a
sensitive marker of Alzheimer disease progression. We selected 24 months as the
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longitudinal interval, as this interval has been previously used for measuring disease
progression in AD.63

2.2 Methods
The automated segmentation approach developed in this study represents an
expedient atrophy change in tissue (EXACT) measurement of the brain. Briefly, EXACT
begins with the use of the expectation maximization (EM) algorithm to remove the skull
and non-brain tissue from each image,64 followed by a multiple atlas-based registration to
identify the MTL volume of interest in a subject’s baseline image, and a Fast Marching
algorithm62 (a type of level set algorithm) to refine the boundary of the MTL using image
features such as the gradient. The definition of the region of interest does not correspond
to a single anatomical structure, but instead is guided by anatomical structures and
refined using clearly identifiable tissue boundaries observed in T1-weighted images. In
contrast, trying to find the boundaries of the hippocampus, a structure with low contrast
compared to surrounding tissue, is difficult.45,65 In addition, inclusion of other structures
within and beyond the hippocampus may provide increased sensitive to early AD
pathology.66 Skull stripping and removal of non-brain tissue is repeated in the subject’s
follow-up images. Then, baseline images are registered to skull stripped follow-up
images. Following registration, the transformation field is used to map the MTL volume
from the baseline image to the follow-up image. The measured volume change in the
MTL is the difference between the baseline and follow-up volume. A schematic
representation of the entire automated segmentation procedure is provided in Figure 2.1.
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Figure 2.1 Block diagram of the EXACT segmentation algorithm.

The EM segmentation is a model-based classification method that uses a Bayesian
classifier.67 The EM segmentation algorithm classifies the brain image into cerebrospinal
fluid (CSF), grey matter (GM) and white matter (WM) according to a probability
distribution and the pixel intensity histogram.68 It was chosen as a pre-processing step to
extract the whole brain. Then the whole brain gray scale images of the atlas, baseline, and
follow-up images were used in the registration step. The EM module from 3Dslicer69-71
(http://www.slicer.org) was used in this study. 3DSlicer is open-source software and
based on the VTK (Visualization Toolkit: http://www.vtk.org) and ITK (Insight
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Segmentation and Registration Toolkit: htpp://www.itk.org) libraries. Although the EM
segmentation method within 3Dslicer is one example of a skull stripping method, others
could also be used. This tool is accessible to the research community and easy to use. We
chose this method of skull stripping because it is automated and does not require
parameter optimization. Other available methods (e.g. BET (Brain Extraction Tool) of
FSL (Functional Magnetic Resonance Imaging of the Brain Software Library))72 require
manual interaction to optimize parameters in some subjects if neck and non-brain
structures remain.
The EXACT method requires the rough outline of the MTL region (using a bounding
box) a priori in each atlas by an expert. This step is performed only once. Eight atlases
were created using subject images from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database. These datasets were chosen visually because images had no visible
rotation and medial temporal lobe atrophy spanned the range normally encountered in the
brain in normal elderly controls (N= 3), subjects with MCI (N= 2) and subjects with AD
(N= 3). The volume of interest (VOI) does not correspond to a specific anatomical
structure. Rather the location is guided by the anatomical structure of interest but it is
defined by clearly identifiable tissue boundaries that are observed in T1-weighted images.
The purpose of the registration step is simply to establish a bounding box around the
MTL region that contains the hippocampus. Then, subsequently a Fast Marching method
is used to identify a gray matter VOI. Accurate segmentation of the hippocampus was not
the goal. Rather the goal is definition of a VOI with clearly defined boundaries. In this
way, tracking atrophy over time is more precise.
To quantify ΔMTL volume between two time points (e.g. a baseline and follow-up
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image) several steps were developed in ITK73,74 (Insight Segmentation and Registration
Toolkit: htpp://www.itk.org). First the skull was removed in all eight atlases, as well as in
the baseline and follow-up images using the EM segmentation algorithm. Then, the atlas
that most closely matched the baseline image was selected by registering each atlas to the
baseline image and choosing the atlas that maximized mutual information (MMI)75
within the local MTL region. The optimum atlas image was then aligned to the baseline
brain image. The alignment was performed using affine transformations and the Demon's
registration method.76 The bounding box encompassing the MTL region defined within
the optimum atlas image was propagated into the baseline image using the deformation
matrix. A Fast Marching algorithm74 was then applied to refine the shape and smooth the
boundary of the MTL VOI. An initialization mask around the region of interest was
delineated. A single seed point was initiated inside the region of interest that was
propagated outwards until it reached the desired boundary. The second step involved
mapping the MTL that was defined on the baseline image to the follow-up image. This
propagation was accomplished by registering the baseline image to its corresponding
follow-up image to produce the required transformation matrix and deformation field.
The defined MTL in the baseline image was then propagated to the follow-up image
using the deformation field. The difference between the volume of the MTL in the
baseline image and follow-up image represented the atrophy that occurred between these
time points. The technique was initially tested using a single image atlas, however we
found that the bounding box failed to completely contain the hippocampus in some
instances. Since public atlases are often created using the average of multiple healthy
brains, such atlases are also not optimal for this application. Instead, we utilized eight
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image sets that showed a wide range of anatomical variance and atrophy (healthy brain,
MCI, and AD). Using this approach we successfully labeled a relevant MTL volume in
all subjects, which we confirmed by visual inspection. In a subset of NEC (N=10), MCI
(N=10), and AD (N=10) subjects a method of label fusion was also tested based on a
majority voting strategy.77,78 Eight label maps were independently produced using atlasbased registration to define the bounding box followed by Fast Marching segmentation to
define the VOI. Finally the VOI was refined by label fusion where majority voting was
used to determine whether a voxel should be included in the final VOI.
It should be noted that the smoothness of the edges of the VOI will depend on the
objective function used to define the VOI, which incorporates a data term and a regularity
term. The data term may include region-based and boundary-based terms. The
regularization term is used to smooth the data term. The regularization term of the
Diffeomorphic Demons registration79 (Appendix A) is a convolution of a Gaussian kernel
and spatial transformation (vector field) to smooth this vector field. In contrast, the Fast
Marching method (a type of level-set method, Appendix B) does not use a regularization
term. However, prior to application of the Fast Marching method, a filter is applied to the
image (curvature anisotropic diffusion image filter),74 which smoothes the noise and
enhances the edges. This approach was used to increase sensitivity to minor volumetric
changes over time.

2.2.1 Study subjects
Data used in the preparation of this article were obtained from the ADNI database
(adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging
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(NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the
Food and Drug Administration (FDA), private pharmaceutical companies and non-profit
organizations, as a $60 million, 5-year public-private partnership. The primary goal of
ADNI has been to test whether serial MRI, PET, other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment and early Alzheimer’s disease. Determination of sensitive and
specific markers of very early AD progression is intended to aid researchers and
clinicians to develop new treatments and monitor their effectiveness, as well as lessen the
time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical
Center and University of California – San Francisco. ADNI is the result of efforts of
many co-investigators from a broad range of academic institutions and private
corporations, and subjects have been recruited from over 50 sites across the U.S. and
Canada. The initial goal of ADNI was to recruit 800 subjects but ADNI has been
followed by ADNI-GO and ADNI-2. To date these three protocols have recruited over
1500 adults, ages 55 to 90, to participate in the research, consisting of cognitively normal
older individuals, people with early or late MCI, and people with early AD. The follow
up duration of each group is specified in the protocols for ADNI-1, ADNI-2 and ADNIGO. Subjects originally recruited for ADNI-1 and ADNI-GO had the option to be
followed in ADNI-2. For up-to-date information, see www.adni-info.org.
We randomly selected 1.5 Tesla T1-weighted volumetric MRI images at baseline and
24 months in 50 NEC, 50 subjects with MCI, and 50 subjects with AD from the ADNI
database to test the algorithm. All images were acquired using a sagittal 3D
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magnetization-prepared rapid acquisition with gradient echo MP-RAGE sequence with
pixel size 0.94mm×0.94mm×1.2mm; flip angle ~8°; TE ~4 ms; TR ~9 ms; TI 1000 ms;
matrix, 256x256; 166 slices.80 Additional image preprocessing included geometric
distortion correction, bias field correction and geometrical scaling. All subjects had the
MMSE, Logical Memory 1 (LM) exam81 and ADAS-cog (https://ida.loni.ucla.edu/)
cognitive assessments at baseline and 24 months interval. The MMSE scores were
between 24-30 for NEC and MCI subjects while the MMSE scores for AD subjects were
between 20-26. The measured change in MMSE and ADAS-cog is the difference
between the baseline and follow-up scores. The major objective of ADNI is to provide a
generally accessible data source for studying longitudinal changes in brain structure and
metabolism.

2.2.2 MTL segmentation
Quantification of ∆MTL volume between baseline and 24 months was performed in
each subject using the EXACT measurement summarized in Figure 2.1. The results were
compared to a measure of hippocampal atrophy provided in the ADNI database produced
by FreeSurfer (http://surfer.nmr.mgh.harvard.edu/). The technical details of the
FreeSurfer procedure were previously published,53 and the complete process for
hippocampus volume measurements using the longitudinal processing pipeline in ADNI
can be found online (http://www.loni.ucla.edu/twiki/bin/view/ADNI/). The hippocampal
volume measurements made using the longitudinal stream of FreeSurfer version 4.4 were
provided to ADNI by the UCSF medical center. An expert (N.R.) also manually
segmented the hippocampus in a subset of data (N=10 NEC, N=10 MCI, and N=10 AD)
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to compare hippocampal volumes to the volume of tissue included by EXACT. The Dice
index82 was calculated using the baseline images for each group.

2.2.3 Statistical analysis
One-way analysis of variance (ANOVA) was performed to compare ∆MTL volume
between the NEC, MCI and AD groups. The association between the ∆MTL from the
EXACT measurement and change in MMSE, LM and ADAS-cog scores were evaluated
using linear regression. The Pearson correlation coefficients were calculated between the
volume changes in MTL from the EXACT measurement and the volume changes in
hippocampus using the FreeSurfer software. Prism GraphPad (Prism, version 5.00;
GraphPad Software, San Diego, CA) was used for the statistical analyses. The receiver
operating characteristic (ROC) was also used to calculate the classification rate between
two groups using the EXACT measurement and the FreeSurfer analysis. The ROC curve
analysis was performed using Prism GraphPad.

2.3 Results
Demographic characteristics are provided in Table 2.1 for all 150 subjects. There
was no difference between group mean ages. The MTL volume (mean ± SEM, mm3) for
the baseline and the follow-up images in the NEC, MCI and AD groups are provided in
Table 2.1. The segmentation of the MTL in one subject using the EXACT method is
shown in Figure 2.2 in the coronal, axial, and sagittal planes along with a 3D rendering.
Similarly, the segmentation of the hippocampus in the same subject using FreeSurfer is
shown in Figure 2.3.
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Figure 2.2 MTL segmentation using the EXACT method
An example segmentation of the MTL using the EXACT method in one subject shown in
Right/Left coronal (A/B), Right/Left axial (C/D) and sagittal (E) orientations. The 3D rendering
of the MTL is shown in (F).
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Figure 2.3 Hippocampus segmentation using the FreeSurfer method
An example segmentation of the hippocampus using the FreeSurfer method in same
subject shown in Right/Left coronal (A/B), Right/Left axial (C/D) and sagittal (E)
orientations. The 3D rendering of the hippocampus is shown in (F).
The manual segmentation of the hippocampus (Figure 2.4) showed that the
hippocampus accounts for only about 40% of the total VOI included by EXACT.
Specifically, the Dice index was 0.43 in the AD group, 0.39 for the MCI group, and 0.45
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for the NEC group. Using an Intel Core 2 Duo processor (3.06 GHz) on an iMac10.1
desktop computer, the total processing time to determine change in MTL volume was ~5
hours using the EXACT method.

Figure 2.4 Comparison between manual hippocampus segmentation and MTL
segmentation using the EXACT method
An example manual segmentation of hippocampus and amygdala and corresponding
MTL segmentation using the EXACT method in anterior (A), middle (B) and posterior
views (C). Amygdala (purple), hippocampus (green), and MTL (yellow) are outlined
separately.
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Table 2.1 Demographic information for study participants.
M: male, SD: standard deviation, SEM: Standard Error of Mean
Diagnosis

Software

NEC

MCI

AD

Number of subject (N)

50

50

50

Age (Mean ± SD)

76.3 ± 5.0

74.5 ± 7.5

76.5 ± 6.4

Sex (M)

27

30

23

Baseline MMSE (Mean ± SD)

29.1 ± 1.0

27.0 ± 1.7

23.3 ± 1.8

29.2 ± 0.9

25.1 ± 3.8

19.6 ± 5.4

ΔMMSE (Mean ± SD)

-0.04 ± 1.1

1.8 ± 3.1

3.7 ± 5.0

Baseline ADAS (Mean ± SD)

5.8 ± 3.3

11.2 ± 4.5

18.0 ± 5.7

5.6 ± 3.2

13.7 ± 6.7

25.0 ± 10.9

0.19 ± 3.3

-2.5 ± 4.9

-7.1 ± 8.4

EXACT

8569.8 ± 136.1

7773.6 ± 243.1

7161.5 ± 231.1

EXACT

8501.6 ±135.1

7586.4 ± 245.3

6861.1 ± 226.0

FreeSurfer

6599.7 ± 104.0

5896.1 ± 147.4

4993.3 ± 143.0

FreeSurfer

6441.2 ± 111.4

5481.0 ± 153.0

4589.9 ± 141.3

24 months Follow-up MMSE
(Mean ± SD)

24 months Follow-up ADAS
(Mean ± SD)
ΔADAS (Mean ± SD)
Baseline MTL volume
3

(Mean ±SEM) mm

24 months MTL Follow-up volume
3

(Mean ± SEM) mm

Baseline hippocampus volume
(Mean ±SEM) mm3
24 months hippocampus Follow-up
volume (Mean ± SEM) mm3
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Figure 2.5 shows the average volume changes over 24 months for the MTL measured
by the EXACT method and the change in the hippocampus measured by FreeSurfer in all
groups. The average volume change measured using the EXACT method was
significantly smaller than that measured using FreeSurfer in NEC (p=0.03), MCI
(p=0.001), and AD (p=0.003). The one-way ANOVA indicated that there was a
significant difference between three groups using the EXACT method (p<0.0001) and
using the FreeSurfer software (p<0.0001). An unpaired t-test showed that using the
EXACT method, there was a significant difference in MTL volume changes between the
NEC and MCI subject groups (p=0.02), between the NEC and AD subject groups
(p<0.0001), and between the MCI and AD subject groups (p=0.02). Similarly, an
unpaired t-test of the FreeSurfer data also showed a significant difference in hippocampus
between the NEC and MCI subject groups (p=0.0003), and a significant difference
between the NEC and AD subject groups (p<0.0001). But no significant difference was
detected between the MCI and AD subject groups.

Figure 2.5 Average volume changes in three groups were measured using the
EXACT (A) and the FreeSurfer (B) methods
The error bars represent the standard error of the mean and asterisks show significant differences
between groups (p<0.05).
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Figure 2.6 shows a significant correlation (r= 0.43, p<0.0001) between the volume
changes in the MTL using the EXACT method and volume change of the hippocampus
using FreeSurfer including data for all groups.
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Figure 2.6 Association between volume changes in MTL and hippocampus volume
changes
Association between volume changes in MTL using the EXACT method and
hippocampus volume change measured using the FreeSurfer method (r = 0.43,
p<0.0001). The 95% confidence intervals for the regressions are shown as dashed lines.
Figure 2.7 shows a significant association between the volume changes in the MTL
measured by the EXACT and the MMSE score (r= 0.24, p=0.003), and between the
hippocampus measured by FreeSurfer and the MMSE score (r= 0.39, p<0.0001). Figure
2.8 shows a significant association between the volume changes in the MTL measured by
EXACT and the ADAS-cog changes (r= -0.25, p=0.002), and between the hippocampus
measured by FreeSurfer and the ADAS-cog changes (r= -0.34, p<0.0001). A significant
correlation between the volume changes in the MTL measured by EXACT and the 24
months LM score (r= -0.39, p<0.0001), and between the hippocampus measured by
FreeSurfer and the 24 months LM score (r= -0.51, p<0.0001) is shown in Figure 2.9.
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Figure 2.7 Association between volume changes and MMSE changes
Association between the volume changes in MTL using the EXACT (A) and the MMSE
score (r= 0.24, p=0.003). Relationship between the volume changes in hippocampus
using FreeSurfer (B) and the MMSE changes score (r= 0.39, p<0.0001). The 95%
confidence intervals for the regressions are shown as dashed lines.

Figure 2.8 Association between the volume changes and ADAS-cog changes
Association between the volume changes in MTL using the EXACT (A) and the ADAScog changes (r= -0.25, p=0.002). Relationship between the volume changes in
hippocampus using FreeSurfer (B) and the ADAS-cog changes (r= -0.34, p<0.0001). The
95% confidence intervals for the regressions are shown as dashed lines.
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Figure 2.9 Association between the volume changes and 24-month LM score
Association between the volume changes in MTL using the EXACT (A) and the 24
months LM score (r= -0.39, p<0.0001). Relationship between the volume changes in
hippocampus using FreeSurfer (B) and the 24 months LM score (r= -0.51, p<0.0001).
The 95% confidence intervals for the regressions are shown as dashed lines.
A comparison of the VOI defined by the EXACT method and the VOI defined when
incorporating label fusion by majority voting is shown in Figure 2.10. With the label
fusion approach the average MTL volume change was 68.0 mm3 greater across all groups
compared to the EXACT method (N=10). With label fusion, the average ΔMTL was 54.9
mm3 in NEC, 380.0 mm3 in MCI, and 384.0 mm3 in the AD groups (ND=10). Using the
EXACT method in the same subject, the average ΔMTL was -49.5 mm3 in NEC, 295.2
mm3 in MCI, and 405.4 mm3 in the AD groups. In the subset of individuals studied, the
average volume change measured using the EXACT and label fusion methods were not
significantly different in NEC (p> 0.05), MCI (p> 0.05), and AD (p> 0.05) groups. A
one-way ANOVA indicated that there was a significant difference between the three
groups using the EXACT method (p<0.001) and using the label fusion method (p<0.01).
An unpaired t-test showed that using the EXACT method, there was a significant
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difference in MTL volume change between the NEC and MCI groups (p=0.004), and
between the NEC and AD groups (p=0.001). Similarly, an unpaired t-test of the label
fusion volumes also showed a significant difference in MTL between the NEC and MCI
groups (p=0.02), and a significant difference between the NEC and AD groups (p<0.05).
In this subset of subjects neither method detected a difference between the MCI and AD
groups.

Figure 2.10 MTL segmentation using the EXACT method and the label fusion
method
An example T1-weighted coronal MRI (A) following segmentation of the MTL using the EXACT
method (B) and the label fusion method (C) in the same subject shown.

A Bland-Altman plot was used to examine the agreement between the EXACT and
FreeSurfer methods. The Bland-Altman plot in Figure 2.11 shows the difference between
the EXACT and FreeSurfer volume change measurements as a function of their average.
The mean bias (108.4) and the 95% limit of agreement (265.8) computed as the mean
bias ± SD of the difference between the two techniques are also shown. The results
indicate that the FreeSurfer technique calculated larger changes in volume than the
EXACT method. The ROC curve analysis between two groups using the EXACT method
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and the FreeSurfer software showed that the ability to classify subjects between NEC and
AD groups with EXACT was slightly lower (76%) compared to FreeSurfer (80%). But,
the ability to classify subjects between MCI and AD groups with EXACT was slightly
higher (60%) compared to FreeSurfer (57%). The Z distribution indicates that there was
no significant difference between the areas under the two ROC curves of NEC vs AD and

ΔVolumeFreeSurfer - ΔVolumeEXACT (mm3)

MCI vs AD (p>0.05).
1500

1000
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-500
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Figure 2.11 Bland-Altman plot between the FreeSurfer and the EXACT method
The mean difference (±SD) between FreeSurfer and EXACT was 108.4 ± 265.8. The bold dashed
line indicates the mean difference and the dashed lines indicate the 95% limits of agreement.

2.4 Discussion
A novel fully automated method for segmentation of the MTL (EXACT) was
developed that combined multiple atlas-based registration with a Fast Marching
algorithm. The EXACT method was used to measure the change in MTL volume for 50
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NEC, 50 subjects with MCI and 50 subjects with AD over a 24 months interval. The
volume changes in the MTL correlated with changes in cognitive function measured
using the MMSE and the ADAS-cog scores, as well as memory performance using the
LM score. The volume of interest measured by EXACT does not correspond exclusively
to the hippocampus.

Rather it is a medial temporal lobe volume to which the

hippocampus contributes ~ 40%. Comparison between manual tracings and the EXACT
VOI indicated that EXACT also includes primarily the amygdala, fibers associated with
the amygdala, and the parahippocampal gyrus.
The absolute change in MTL volume measured using the EXACT approach was
slightly lower than the change measured by FreeSurfer in the hippocampus. However,
this result was expected as FreeSurfer has been shown to significantly overestimate the
rate of measured mean atrophy in NEC, MCI and AD groups compared to multi-template
hippocampal segmentation.36,83 When comparing the rate of atrophy measured over two
years with EXACT to other methods, the values appear lower due in part to a larger MTL
baseline measurement; the VOI defined by EXACT also includes tissue outside the
hippocampus. Specifically, the mean MTL rate of atrophy measured over two years by
EXACT was 0.7% in NEC, 2.7% in MCI and 4.2% in AD subjects while FreeSurfer
measured hippocampal atrophy of 2.5% in NEC, 5.9% in MCI, and 8.0% in AD.
Similarly, the 24 month mean rate of atrophy measured by EXACT was smaller than that
recently reported by Nestor et. al.36 in the hippocampus using multi-atlas based
segmentation: 2.5% for NEC (n= 173), 5.0% for MCI (n= 253) and 7.9% for AD (n=
111). These differences may also be explained by differing sample sizes. More
importantly, using the EXACT method, differences were detected between all three
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groups (NEC, MCI, AD) while the FreeSurfer measurement only detected differences
between NEC and MCI, as well as NEC and AD. The observed significant difference in
∆MTL volume between MCI and AD subjects suggests that ∆MTL volume may provide
useful to differentiate between MCI and AD subjects.

However both EXACT and

FreeSurfer showed similar classification accuracy for NEC versus AD (76-80%) and for
MCI versus AD (57-60%).

Previous studies have also shown similar results.

For

example, Shen et. al.84 performed a fully automated atlas-based segmentation using a
template-based approach to obtain normalized hippocampal and amygdala volumes
between subjects with AD, subjects with amnestic MCI (aMCI) and healthy control
subjects. By using the area under the ROC curve on normalized hippocampus volume,
they achieved a classification rate of 86-90% for the left hippocampus and of 85-87% for
the right hippocampus for AD versus controls. However, they did not compare the
classification rate between their subjects with aMCI and AD as well as examine the
automated segmentation results with manual tracing. The EXACT method showed that
the area under the ROC curve on volume changes was 78% in the left MTL and 75% in
the right MTL between NEC and AD groups. However, a statistical comparison of the
area under the ROC curves is not possible.
Both the EXACT and FreeSurfer techniques produced a significant relationship
between change in volume and the change in MMSE and the ADAS-cog cognitive scores
as well as 24 months LM score. With the EXACT method a positive correlation was
observed between the volume changes in MTL and the change in MMSE score, and an
inverse correlation was observed between the change in MTL and the change in ADAScog and LM scores, suggesting that MTL atrophy is related to cognitive function and
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memory performance. Previous studies using manual or semi-automated measures of
MTL volumes have also shown a significant correlation between the rate of clinical
decline and MTL atrophy in elderly patients over 12 months.85,86 Arlt et. al. showed
correlations between hippocampus volume and neuropsychological tests for aMCI and
AD groups.87 However, they did not investigate the classification rate of this fully
automated technique or comparison with manual segmentation. Wolz et. al.88 proposed an
automated method to measure hippocampal atrophy by segmenting longitudinal MR
images from the ADNI database. They used an energy function based on Markov random
fields (MRF) in combination with the graph cuts method41 and showed a significant
correlation (r= 0.30, p<0.001) between MMSE changes and hippocampal volume
changes after 1 year. Similarly in the current study, we found a significant association
between MTL volume changes after 2 years and the change in MMSE score (r= 0.24,
p=0.003). Although both studies demonstrated a similar association, there are several
important differences between the approaches. First, we segmented the VOI in the
baseline image and propagate this VOI to follow-up image. In contrast, Wolz et. al.88
proposed a method that segments hippocampus simultaneously in all longitudinal images.
Second, their initial probabilistic atlas was created from healthy subjects, while EXACT
selects the best atlas from a series of eight possibilities. Finally, they used the graph cuts
method41 to segment longitudinal MR images, while we applied the Fast Marching
method to the baseline images.
Several studies have performed manual or semi-automated segmentation of brain
structures, which is time-consuming and is characterized by low intra- and inter-observer
reproducibility depending on the level of experience of the observers.89-91 Although
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several automated hippocampus segmentation methods have been proposed,92,93 these
studies used single atlas-based segmentation potentially decreasing accuracy. In contrast,
the current study used eight separate atlases to increase segmentation accuracy. Since
EXACT requires significantly less processing time, it would be advantages in situations
where large datasets must be analyzed.
Potential limitations of the algorithm are that the segmentation of the MTL in the
baseline and follow up images are not independent (baseline images are registered to
follow-up images). However this approach was taken to increase the precision of the
atrophy measurement in this small structure. It should also be noted that the contour of
the volume of interest is treated differently in the baseline and follow-up images. We
expect that volumetric changes that occur between time points in one individual will be
subtle. Therefore, we chose to use a regularization term in the diffeomorphic registration
that was less severe than the smoothing filter used with the Fast Marching method so that
the method would be sensitive to minor volumetric changes. Since the EXACT
measurement is designed to be sensitive to atrophy, accurately defining the hippocampus
is less important than sensitivity to change within the prescribed volume. Also, only a
small number (eight) of atlases were used for selection, which should be increased for
larger datasets. However the use of a small number of atlases is likely not a major
limitation because the accuracy of the definition of the MTL is less important than
sensitivity to change over time. Including more atlases may further increase the
robustness of the technique in cases of extreme anatomical variability, however would
also increase computation time. Optimizing the number of atlases will be the focus of
future work. The number of atlases used can impact the quality of the final segmentation.
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The purpose of the atlas registration is to define a bounding box around the medial
temporal lobe region of interest. As such, the demands on this registration step are light.
However in cases of severe atrophy, the bounding box may fail to include the
hippocampus if there are significant differences between the image and the atlas. This
limitation was overcome in the current study by using multiple atlases with varying
anatomy.

Using eight atlases that spanned a wide range of atrophy conditions we

successfully defined a MTL region label map in all subjects. Using an atlas fusion
technique did not change the results and increased computation time. Finally, the method
described in the current study is biased, since the baseline and follow-up volumes are
measured using different regularization functions. Recently, several unbiased
methods88,94,95 have also been proposed for longitudinal studies.

2.5 Conclusions
In the present study, a fully automated longitudinal MTL atrophy measurement
called EXACT was developed. The EXACT measurement showed significant differences
in MTL atrophy over two years in normal elderly controls, subjects with mild cognitive
impairment, and subjects with Alzheimer’s disease. The MTL atrophy also correlated
with decline in cognitive performance. This method is applicable to large datasets and
could be incorporated in clinical evaluation in the future.
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2.6 Appendices
Appendix A.
In Demons registration, an energy function is optimized to align two images by
introducing correspondences between image pixels and applying a regularization term as
prior knowledge to smooth the transformation of spatial points. The energy function can
be formulated as shown in Eq. (2.1) and described in.79
E(c, s) =

1
1
1
Sim(F, M ! c) + 2 dist(s, c)2 + 2 Re g(s)
2
σi
σx
σr

(2.1)

Where σ x represents the spatial uncertainly on the correspondences between image
pixels, σ i = F( p) − M  c( p) , dist(s, c) = c − s , the regularization term Re g(s) = ∇s

2

and Sim(.,.) is a similarity metric using the transformation of spatial points given by Eq.
(2.2) in.79
Sim(F, M ! s) =

1
1
2
F −M !s =
2
2 Ωp

∑

F( p) − M (s( p))

2

(2.2)

p∈Ω p

where Ω p is the region of overlap between F and M  s . M  s is a transformation of
spatial points (s) belonging to the moving image M. To optimize Eq. (2.1) a spatial
transformation is chosen. Given s, the vector field (u) is updated by minimizing Eq. (2.3)
with respect to u using a Gauss-Newton iterative method.79 Then the regularization is
measured by convolution of a Gaussian kernel and vector field. This procedure performs
iteratively till convergence.
2

Escorr (u) = F − M ! (s + u) +

σ i2
u
σ x2

2

(2.3)
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This Demons algorithm is made Diffeomorphic by computing an exponential of the
vector field u with the spatial points s, prior to regularization.

Appendix B.
Details of the Fast Marching segmentation method can be found in.62,74,96 Briefly, in
the Fast Marching segmentation method, the goal is to solve the Eikonal equation
∇T F1 = 1 . In its discrete form, it is given by Eq. (2.4) presented in.96-98

1
2
1 {i, j,k}

F

−x
2
+x
2
−y
2
= max(D{i,
j,k}T, 0) + min(D{i, j,k}T, 0) + max(D{i, j,k}T, 0) +

+y
2
−z
2
+z
2
min(D{i,
j,k}T, 0) + max(D{i, j,k}T, 0) + min(D{i, j,k}T, 0)

where D − xT (i, j, k) = T (i, j, k) − T (i −1, j, k) , D + xT (i, j, k) = T (i +1, j, k) − T (i, j, k) and
similarly for the y and z directions. In practice, the method propagates a contour curve in
2D or a contour surface in 3D with the speed function F1. Where T (i, j, k) is the time
when the speed function reaches voxel (i, j, k) .
The Fast Marching method has two phases: an initialization and propagation step.
Each voxel has a value for T that is updated as the contour propagates. Voxels meeting a
defined time threshold are included within the contour. The speed term in the differential
equation is determined from the gradient magnitude. The curve propagates slowly near
large image gradients but moves quickly when image gradients are small. Using this
strategy, the contour propagates quickly until it nears the edge of an anatomical structure
at which point it slows down. The contour propagates continuously over time and stops
once a defined time threshold has been reached.74

(2.4)
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CHAPTER 3: Spontaneous blood oxygen level dependent MRI
signal variations are decreased in Alzheimer disease
The work presented in this chapter is in preparation for submission for publication.

Samaneh Kazemifar, Kathryn Manning, Nagalingam Rajakumar, Francisco A. Gómez,
Andrea Soddu, Michael J. Borrie, Ravi S. Menon and Robert Bartha PhD

3.1 Introduction
Alzheimer disease is considered to be a progressive neurodegenerative condition
clinically characterized by cognitive dysfunction and memory impairments1 that appear
to result from the pathological accumulation of amyloid plaques and neurofibrillary
tangles.2,3 Brain atrophy measured by magnetic resonance imaging (MRI) has been
established as an important biomarker associated with disease progression and treatment
response.4-6 Another established biomarker is reduced regional uptake of
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F labeled

fluorodeoxyglucose (FDG) measured using positron emission tomography (PET),7
indicating lower glucose metabolism in Alzheimer’s disease.8,9
Neuronal activity can also be inferred from blood oxygen level dependent (BOLD)
contrast as exploited in functional MRI (fMRI). More recently, resting-state (RS)-fMRI
measures of spontaneous low frequency fluctuations (< 0.1 HZ) in the BOLD signal have
been used to identify functionally connected brain regions (networks) without the
performance of an overt task.10,11 Smith and colleagues12,13 have shown that several
resting state networks can be identified, and may be altered in Alzheimer’s disease. For
example, multiple studies have found resting RS-fMRI can be used to show disrupted
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connectivity between the hippocampus and other brain regions in Alzheimer
disease.12,14,15 Furthermore, the interconnectivity of brain regions can be used to classify
subjects with Alzheimer disease, amnestic mild cognitive impairment, and healthy
elderly.16
A number of different statistical and mathematic approaches have been used to infer
functional connectivity from RS-fMRI data. One common approach is to use the a-priori
selection of a seed region of interest (ROI)17-19 to determine the correlation between the
mean BOLD signal time course within the ROI and the BOLD signal time courses of all
other pixels in the brain. However the requirement for a-priori seed selection makes it
difficult to examine the functional connectivity across the whole brain. Another popular
multivariate technique for analyzing whole brain connectivity is independent component
analysis (ICA).20-22 This approach does not require a-priori information and decomposes
the BOLD signal into a set of spatial and temporal components that are maximally
statistically independent.23 The ICA method is also an efficient approach to extract
scanner noise, as well as physiological and motion artifacts from the BOLD signal.24 One
of the major challenges with the ICA technique is to determine which components
represent physiologically relevant networks, and which components represent noise.
However methods now exist to differentiate neuronal from non-neuronal components.25
Brain regions associated with the default mode network (DMN) have been repeatedly
implicated in the pathogenesis of Alzheimer’s disease.12,26 FDG-PET studies have shown
reduced glucose metabolism in the medial temporal cortex, hippocampus, and posterior
cingulate cortex.27-29 Decreased functional connectivity in the DMN has also been
associated with increased amyloid deposition measured using Pittsburgh compound B
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PET.30,31 In addition, several studies in healthy controls have shown a relationship
between glucose metabolism measured by PET and the RS-fMRI signal. For example,
Di et. al. showed that metabolic activity was correlated with IC maps of the BOLD signal
in regions that are functionally connected.32 Similarly, Tomasi et. al.33 measured the
amplitude of the RS-fMRI signal and glucose metabolism by FDG-PET and
demonstrated that higher metabolism was correlated with a higher amplitude of the RSfMRI signal in the cerebellum, occipital, and parietal cortices. Finally, Riedl et. al.34
found a correlation between local brain activity in specific regions of interest measured
from FDG-PET data and functional connectivity measured by RS-fMRI using seed-based
methods.
Previous RS-fMRI studies have shown a reduction in functional connectivity
between structures based on the strength of the correlation in the BOLD signal.18,35 Here,
we define a novel metric of brain activity based on first-order texture feature defined as
the standard deviation of the magnitude of the BOLD fluctuation. The purpose of this
study was to determine whether this new metric could be used to accurately differentiate
healthy individuals from people with mild Alzheimer disease. The hypothesis is that the
fluctuation of the magnitude of the BOLD signal as a function of time is related to
neuronal activity and therefore will also correlate with FDG-PET measures of glucose
metabolism. The goal is to demonstrate the efficacy of a new biomarker of Alzheimer’s
disease based on the fluctuation of the magnitude of the RS-fMRI signal. Furthermore,
we examined the association between the fluctuation magnitude of the neuronal derived
RS-fMRI signal and FDG-PET.
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3.2 Theory
In this study, we propose a brain activity measurement derived directly from the RSfMRI signal. The RS-fMRI signal can be represented as an i x v matrix, where i
represents each pixel, and v represents the number of volumes acquired in the fMRI
acquisition. The ICA method decomposes the RS-fMRI signal into: 1) an i x n matrix of
independent components (IC) spatial maps, where n represents the number of
components, and 2) an n x v matrix of mixing weights (W) or IC time-courses. Here, the
number (k) of legitimate ICs were identified using a support vector machine (SVM)
classifier25 that included only the neuronal components (NC) with goodness-of-fit (GoF)
≥ 0.01 (Figure 3.1A). The weighting function for each neuronal component, Wk(tv) is
then multiplied (Hadamard product, Eq. 3.1, Figure 3.1B) with the equal length vector
given by the RS-fMRI time series for each pixel, Si(tv), generating a new vector of equal
length BSAi,k(𝑡! ):
𝐵𝑆𝐴!,! (𝑡! ) =    𝑆! (𝑡! )    ∘ 𝑊! (𝑡! )                                                                                                                                                                                                  [3.1]
where BSAi,k represents the BOLD signal amplitude (BSA) for each neuronal
component k in pixel i. Then, the standard deviation (SD) is calculated for BSAi,k and is
multiplied with the neuronal component (NCi,k) (Figure 3.1C). The sum of this metric
(Eq. 3.2, Figure 3.1D) for all neuronal components in a pixel represents the neuronal
activity and is used to produce a neuronal activity map.
!

𝑁𝑒𝑢𝑟𝑜𝑛𝑎𝑙  𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦! =   

𝑆𝐷(𝐵𝑆𝐴!,! (𝑡! ))  ×  𝑁𝐶!,!                                                                                                           [3.2]
!!!
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Figure 3.1 Schematic diagram of the brain activity metric calculated from the RSfMRI signal in one pixel
The signal shown is a graphical representation of the vector data. (A) Neuronal time course
(NTC) are defined by the ICA and verified using a support vector machine classifier. (B) The
Hadamard product of each neuronal time course is taken with the RS-fMRI signal. (C) The
standard deviation of the resulting signal is multiplied by the neuronal component. (D) The
square root of the contribution of each NTC is added to create a measure of neuronal activity.

3.3 Methods
3.3.1 Study subjects
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 as a public-private partnership, led by Principal Investigator Michael
W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic
resonance imaging, positron emission tomography, other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment and early Alzheimer’s disease.
To test the algorithm, this study included data from 15 normal elderly controls (NEC)
and 15 subjects with probable Alzheimer disease of mild severity obtained from the
ADNI database. We included participants that had 3.0 Tesla T1-weighted anatomical
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scans and10-minute RS-fMRI data acquisitions. A subset of this group (13 NEC, and 11
subjects with mild Alzheimer disease) also had an FDG-PET scan available. Structural
T1-weighted images were obtained using a sagittal 3D magnetization-prepared rapid
acquisition

with

a

gradient

echo

MP-RAGE

sequence

with

pixel

size

1mm×1mm×1.2mm; flip angle ~9°; TE ~4 ms; TR ~7 ms; matrix, 256x256; 170
slices.36RS-fMRI scans were acquired using a single shot echo planer imaging (EPI)
pulse sequence with pixel size 3.3mm×3.3mm×3.3mm; flip angle 80.0°; TE 30 ms; TR
~3000 ms; matrix = 64x64; 48 slices.37 FDG-PET images were acquired using similar
protocols on all PET scanners but varied somewhat in resolution, spacing, and dimension.
However images were normalized and motion corrected38 prior to analysis. The FDGPET scans consisted of six-5 minute frames acquired starting 30 minutes after FDG
injection.38 All frames were registered to the first frame and then averaged to produce a
single static image. All subjects were also evaluated with the mini mental state
examination (MMSE)39 to assess cognition. In addition, CSF biomarkers including total
Tau protein (Tau), phosphorylated Tau protein (P-Tau) and amyloid-β (Aβ1-42) were
obtained for all subjects (https://ida.loni.usc.edu/).

3.3.2 RS-fMRI analysis
The brain was extracted from the RS-fMRI data and the anatomical T1-weighted
images using the brain extraction tool (BET) in the FSL software (functional MRI of the
brain (FMRIB) Software Library, Department of Clinical Neurosciences, University of
Oxford, UK, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL). The brain extracted fMRI data
were preprocessed, aligned and co-registered to the MNI-152 space using the fMRI
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expert analysis tool (FEAT) in FSL. An initial smoothing (full-width half-maximum of 6
mm) was applied before ICA decomposition. The ICA method (30 components) was
performed using the group ICA of the fMRI toolbox (GIFT).40 ICA was followed by a
multiple-template matching technique and neuronality test to identify neuronal
components. The multiple-template matching technique and neuronality test was
implemented by Demertzi and colleagues.25 Then, a brain activity map was constructed
from the neuronal components as described in the Theory section and co-registered to the
MNI-152 standard image using linear and non-linear registration methods. Coregistration of the brain activity map to the anatomical image was conducted using
Statistical Parametric Mapping (SPM8, Wellcome Department of Neurology, London,
UK; www. fil.ion.ucl.ac.uk/spm). ROIs were defined in the MNI-152 image using the
structural segmentation method called FMRIB’s integrated registration and segmentation
tool (FIRST) in FSL because it is easily accessible to the research community and
automated. Finally, the mean intensity from each ROI in the brain activity map was
measured. A schematic representation of the steps involved in making the brain activity
measurement is provided in Figure 3.2.

98

Figure 3.2 Brain activity from RS-fMRI. Schematic diagram of the brain activity
(BOLD signal amplitude) measurement in different brain regions
(A) Steps involved in calculating the brain activity maps from the RS-fMRI. (B) Regions of
interest extracted from MNI-152 space. (C) Activity maps within each region of interest from one
subject.

3.3.3 Volumetric analysis
The FSL software was used to measure the volumes of the accumbens, amygdala,
hippocampus, caudate nucleus, thalamus, pallidum, putamen, and whole brain from the
T1-weighted image of each subject using a method similar to that previously described.41
The volumes were normalized to the whole brain volume in each subject.
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3.3.4 FDG-PET analysis
The brain was also extracted from the FDG-PET images using the BET tool in FSL.
A partial volume correction method was applied to each data set using partial volume
correction structural functional synergistic resolution recovery (PVC_SFSRR) software.42
This software performs pre-processing steps including co-registration of the FDG-PET
with the structural image, segmentation and smoothing (8 mm), and finally partial
volume correction. The corrected FDG-PET image was co-registered to the MNI-152
template. The predefined ROIs in the MNI-152 image were applied to the co-registered
FDG-PET image. The standardized uptake value (SUV) of each ROI was then
normalized to the mean SUV of the cerebellum to obtain the SUV ratio (SUVR) as this
has been previously shown43 to be unchanged in healthy subjects at the early stages of
Alzheimer disease.
3.3.5 Statistical analysis
Prism GraphPad (Prism, version 6.00; GraphPad Software, San Diego, CA) and
Matlab toolbox (version R2010a) were used for the statistical analyses. One-way
ANOVA was used to compare brain activity between the NEC and Alzheimer disease
groups (p <0.05 considered significant). If a significant group effect was observed, the pvalues associated with follow-up group comparisons between brain regions were
Bonferroni corrected for multiple comparisons. The association between the brain
activity measured from the RS-fMRI, MMSE score, and CSF biomarkers were evaluated
using linear regression. The Pearson correlation coefficients were calculated between the
brain activity in gray matter using RS-fMRI and FDG-PET and considered significant
with p <0.05.
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3.3.6 Classification model
To determine if the RS-fMRI derived brain activity measurement was a suitable
biomarker to differentiate patients with mild Alzheimer disease and healthy elderly
controls, a SVM classifier was used. Specifically, a linear SVM44 was trained and tested
on the feature space. Regions of interest were selected based on the observed differences
between groups for either the brain activity metric or FDG-PET measured glucose
metabolism. A leave-one-out-test was used as a cross-validation to predict the label for
each test subject (not involved in the training phase). The accuracy, sensitivity, and
specificity were determined after each subject was assessed as the test subject. In the first
analysis, RS-fMRI brain activity in the hippocampus and accumbens, FDG-PET in the
hippocampus, and hippocampal volume were evaluated separately. In a second analysis,
FDG-PET and RS-fMRI modalities were evaluated independently incorporating data
from both the hippocampus and amygdala. In a third analysis, we combined the
volumetric and RS-fMRI information from the hippocampus and accumbens.

3.4 Results
3.4.1 Brain maps of Neuronal activity and glucose metabolism
Demographic characteristics are provided in Table 3.1 for all 30 subjects. There was
no difference between group mean ages, however as expected, there was a significant
difference in the MMSE score (p<0.0001, two-tailed t-test) between the two groups.
Montreal neurological institute-152 (MNI-152) template T1-weighted images (Figures
3.3A, 3.3B) in coronal, sagittal, and axial planes are shown with corresponding
standardized uptake value ratio (SUVR) glucose metabolism maps from the FDG-PET
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scan in one healthy subject (Figure 3.3C) and the healthy group average (Figure 3.3G); as
well as one subject with Alzheimer disease (Figure 3.3D) and the Alzheimer disease
group average (Figure 3.3H). Corresponding brain activity maps measured from the RSfMRI in the same subjects (Figures 3.3E, 3.3F) and group averages (Figures 3.3I, 3.3J)
are also provided. There is a visible decrease in signal in the subject with Alzheimer
disease throughout the brain measured by both modalities.
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Table 3.1 Demographic information for study participants.
RS-fMRI

RS-fMRI

FDG-PET

FDG-PET

NEC

Alzheimer disease

NEC

Alzheimer disease

Number of subject (N)

15

15

13

11

Age (years) (Mean±SD)

73.5 ± 6.2

73.3 ±8.0

74.4 ± 6.1

70.9 ± 7.2

MMSE (Mean±SD)

28.9 ± 1.2

21.6 ± 2.1*

29.0 ± 1.1

21.8± 2.3*

Sex (F)

10

10

9

7

Tau (pg/ml) (Mean±SEM)

66.3± 9.8

164.5±22.8**

63.8±9.6

182.5±28.2**

P-Tau (pg/ml) (Mean±SEM)

38.9 ± 10.0

62.0±7.7

40.7±11.1

68.1±9.5

Aβ1-42 (pg/ml) (Mean±SEM)

192.5± 16.1

132.3±5.4**

179.0±15.0

131.2±7.3**

*p<0.05 (two-tailed) and **adjusted p value (Bonferroni) between NEC and Alzheimer
disease within a single imaging modality
F= female; SEM= standard error of mean, SD= standard deviation, NEC= normal elderly
controls, FDG-PET=

18

fludeoxyglucose-PET, RS-fMRI= resting state functional MRI,

MMSE= mini mental state examination, P-Tau= phospho-Tau, Aβ1-42= amyloid beta1-42
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Figure 3.3 Brain activity and glucose metabolism maps
MNI-152 T1-weighted anatomical images in coronal, sagittal, and axial orientations (A, B).
Corresponding FDG-PET SUVR images of glucose metabolism from a healthy subject (C), and
healthy group average (G); a patient with Alzheimer disease (D), and the Alzheimer disease
group average (H). Brain activity maps obtained using RS-fMRI in the same healthy subject (E),
and the healthy group average (I) and the patient with Alzheimer disease (F), and the Alzheimer
disease group average (J).

3.4.2 Comparison of regional brain activity and glucose metabolism
The average brain activity measured from RS-fMRI (Figure 3.4) is shown for the
cerebellum, amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and
putamen regions for the NEC and Alzheimer disease groups. Similarly, the average
relative rate of glucose metabolism (Figure 3.5) is provided for the same regions
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measured by FDG-PET for the NEC and Alzheimer disease groups. A one-way ANOVA
indicated that there was a significant difference between the two groups in RS-fMRI
brain activity (p<0.0001) and FDG-PET measured glucose metabolism (p<0.0001). In
follow-up comparisons, the difference in brain activity measured by RS-fMRI in both
sides of the accumbens (adjusted p=0.04) and differences in relative glucose metabolism
measured using FDG-PET in the amygdala (adjusted p=0.02), and hippocampus
(adjusted p=0.006) remained significant following Bonferroni correction. A one-way
ANOVA indicated that there was also a significant difference between these groups in
the Tau, P-Tau and Aβ1-42 cerebral spinal fluid (CSF) levels (p<0.0001). Follow-up
comparisons showed that there were significant differences in both Tau (adjusted
p<0.0001), and Aβ1-42 (adjusted p=0.006) following Bonferroni correction for multiple
comparisons. As expected, a one-way ANOVA also showed a significant difference in
normalized brain volumes between the NEC and Alzheimer disease groups (p<0.0001).
Follow-up comparisons showed significant differences in normalized volume measured
using MRI in the hippocampus (p=0.01) between the two groups.
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Figure 3.4 Regional brain activity
The average brain activity measured by RS-fMRI in NEC and Alzheimer disease subjects in the
cerebellum, amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen. The
error bars represent the standard error of the mean and asterisks show significant differences
between groups (Bonferroni adjusted p value).
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Figure 3.5 Regional glucose metabolism
The average glucose metabolism measured by FDG-PET SUVR in NEC and Alzheimer disease
subjects in the amygdala, thalamus, accumbens, caudate, pallidum, hippocampus, and putamen.
The error bars represent the standard error of the mean and asterisks show significant differences
between groups (Bonferroni adjusted p value).

3.4.3 Comparison of neuronal components in NEC and Alzheimer disease groups
The average ± SD of the number of neuronal components was 6.4 ± 1.5 for the NEC
group and 5.0 ±1.2 for the Alzheimer disease group. Unpaired t-test (two-tailed) showed
significantly fewer neuronal components in the Alzheimer disease group compared to the
NEC group (p=0.007). Pooling all subjects, the average number of neuronal components
was positively correlated with MMSE score (r= 0.30, p=0.002). The average ± SD of the
RS-fMRI neuronal activity (Eq. 3.2) summed across all neuronal components in whole
brain was 54.8 ± 18.3 in the NEC group and 40.6 ± 10.4 in the Alzheimer disease group.
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Unpaired t-test (two-tailed) showed significantly lower neuronal activity in the Alzheimer
disease group compared to the NEC group (p=0.01) (Figure 3.6).

Figure 3.6 Component specific brain activity maps in one healthy subject and one
subject with Alzheimer disease
Each image represents the square root of the standard deviation of the magnitude of the BOLD
signal fluctuation. In this example, data from each identified neuronal component is provided in
a different row. Eight neuronal components were identified in the healthy subject while only six
neuronal components were identified in the subject with AD.

3.4.4 Association between neuronal activity and cognitive function
The relationship between RS-fMRI brain activity and clinical cognitive
measurements are shown in Figure 3.7 when pooling all groups. There was a significant
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correlation between the MMSE score and brain activity in the cerebellum (r= 0.50,
p=0.007), amygdala (r= 0.47, p=0.009), thalamus (r= 0.42, p=0.02), accumbens (r=0.48,
p=0.008), caudate (r= 0.41, p=0.02), pallidum (r= 0.44, p=0.01), hippocampus (r= 0.44,
p=0.01), and putamen (r= 0.41, p=0.02).

Figure 3.7 Relationship between mean brain activities measured using RS-fMRI and
cognition function
The 95% confidence intervals for the regressions are shown as dotted lines. Association between
MMSE score and brain activity in cerebellum (r= 0.50, p=0.007, A), amygdala (r= 0.47, p=0.009,
B), thalamus (r= 0.42, p=0.02, C), accumbens (r= 0.48, p=0.008, D), caudate (r= 0.41, p=0.02, E),
pallidum (r= 0.44, p=0.01, F), hippocampus (r= 0.44, p=0.01, G), and putamen (r= 0.41, p=0.02,
H).
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3.4.5 Association between neuronal activity and Aβ 1-42
The relationship between RS-fMRI brain activity and Aβ1-42 CSF level is shown in
Figure 3.8 for all subjects. There was a significant correlation between the RS-fMRI
brain activity and Aβ1-42 in the cerebellum (r= 0.40, p=0.03), amygdala (r= 0.51,
p=0.004), accumbens (r= 0.37, p=0.04), pallidum (r= 0.41, p=0.02), and putamen (r=
0.41, p=0.02).

Figure 3.8 Relationship between mean brain activity measured using RS-fMRI and
CSF derived Amyloid Beta1-42.
The 95% confidence intervals for the regressions are shown as dotted lines. Association between
the brain activity and Aβ1-42 in the cerebellum (r= 0.40, p=0.03, A), amygdala (r= 0.51, p=0.004,
B), accumbens (r= 0.37, p=0.04, C), pallidum (r= 0.41, p=0.02, D), and putamen (r= 0.41,
p=0.02, E).
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3.4.6 Association between neuronal activity and glucose metabolism
A voxel by voxel correlation between gray matter RS-fMRI brain activity and the
rate of glucose metabolism from the FDG-PET is shown in Figure 3.9 for one NEC (r=
0.81, p<0.0001) and subject with Alzheimer disease (r= 0.77, p<0.0001). Correlations
were similar in all subjects (Figures 3.10 and 3.11). The average r- value ± SD associated
with the correlation between gray matter activity measured using RS-fMRI and the rate
of glucose metabolism measured using FDG-PET was 0.77 ± 0.04 for the NEC group and
0.73 ± 0.03 for the Alzheimer disease group. The average y-intercept ± SD for the NEC
group was 0.23 ± 0.03 and for the Alzheimer disease group was 0.23 ± 0.03.

Figure 3.9 Relationship between glucose metabolism using FDG-PET and brain
activity measured by RS-fMRI
Voxel by Voxel correlation of pixel intensity in gray matter (r= 0.81, p<0.001) from a healthy
subject (A) and a patient with Alzheimer disease (B) (r= 0.77, p<0.001) between brain activity
using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR.
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Figure 3.10 Correlation of pixel intensity between RS-fMRI and FDG-PET SUVR in
healthy group
Voxel by voxel correlation of pixel intensity in the gray matter of healthy subjects between brain
activity using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR.

Figure 3.11 Correlation of pixel intensity between RS-fMRI and FDG-PET SUVR in
Alzheimer disease group
Voxel by voxel correlation of pixel intensity in the gray matter of Alzheimer disease subjects
between brain activity using RS-fMRI and corrected glucose metabolism using FDG-PET SUVR.
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3.4.7 Comparison of classification accuracy
The classification accuracy of subjects using brain activity measured by RS-fMRI
and relative glucose metabolism rate measured using FDG-PET is provided in Table 3.2.
The greatest classification accuracy, sensitivity, and specificity were obtained when using
FDG-PET measurement from the hippocampus. The classification model that used
glucose metabolism in the hippocampus measured by FDG-PET achieved 85% average
accuracy, 84% sensitivity and 85% specificity (Table 3.2). The models that used brain
activity in the hippocampus or accumbens resulted in a lower accuracy, sensitivity, and
specificity (Table 3.2). However, the model that combined normalized hippocampal
volume and neuronal activity of RS-fMRI from the hippocampus achieved 80% average
accuracy, 72% sensitivity and 89% specificity, providing a similar accuracy and
specificity to that observed with FDG-PET glucose metabolism in the hippocampus.
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Table 3.2 Classification results for RS-fMRI brain activity, glucose metabolism and
volumetric measurements
Glucose metabolism measured by FDG-PET SUVR, and normalized volume measured using
MRI.

SVM_linear (leave-one-out-test)

Accuracy

Sensitivity

Specificity

RS-fMRI (Hippocampus)

0.75

0.70

0.78

RS-fMRI (Accumbens)

0.56

0.42

0.68

RS-fMRI (Hippocampus, and Amygdala)

0.65

0.57

0.71

FDG-PET (Hippocampus)

0.85

0.84

0.85

FDG-PET (Hippocampus, and Amygdala)

0.76

0.84

0.68

MRI (Hippocampus)

0.67

0.64

0.70

RS-fMRI (Accumbens) + MRI (Hippocampus)

0.70

0.63

0.73

RS-fMRI (Hippocampus) + MRI (Hippocampus)

0.80

0.72

0.89

SVM= support vector machine, FDG-PET=
state functional MRI, ROI= region of interest.

18

fludeoxyglucose-PET, RS-fMRI= resting
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3.5 Discussion
In this study we define a new metric related to neuronal activity based on the square
root of the temporal standard deviation of the RS-fMRI signal summed across all
neuronal components within a pixel. As a proof of principle, this new RS-fMRI based
biomarker was used to compare brain activity in normal elderly subjects and patients with
mild Alzheimer disease. The brain activity measurement is dependent on both the number
of neuronal components and the temporal fluctuation associated with each component.
Overall lower brain activity was observed in the mild Alzheimer disease group,
particularly within the accumbens. A similar comparison in the same subjects using
FDG-PET also showed overall group differences indicating lower glucose metabolism in
the amygdala, and hippocampus. In a pixel-by-pixel analysis, brain activity derived from
RS-fMRI was found to be strongly correlated with glucose metabolism measured by
FDG-PET in gray matter.
The FDG-PET results from the current study are consistent with previous FDG-PET
studies that have shown reduced glucose metabolism in subjects with Alzheimer
disease.28,45 Reduced glucose metabolism is also observed in the posterior cingulate,
temporal, parietal lobes and later the frontal lobe.28,46 Mosconiet. al.47 showed that
glucose metabolism in the hippocampus and the entorhinal cortex is also reduced in the
preclinical stage of Alzheimer disease. In addition, Jagust et. al.48 has demonstrated that
medial temporal and parietal glucose metabolism predicts cognitive decline. Glucose
consumption measured by FDG-PET is also linearly associated with neuronal activity.49
Therefore glucose consumption is considered an important biomarker in the detection of
presymptomatic Alzheimer disease.50
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A few RS-fMRI studies have also examined functional network activity in healthy
subjects compared to people with Alzheimer disease. Seed based analysis studies17,18
showed decreased functional connectivity (FC) in the medial temporal cortex, prefrontal
cortex, precuneus, posterior cingulate, hippocampus, and thalamus in people with
Alzheimer disease. Similar studies using ICA methods demonstrated reduced FC in
precuneus, posterior cingulate, and parietal lobe in amnestic mild cognitive impairment
(aMCI) subjects51 while Zhou et. al.52 showed decreased FC in the default mode network
including the hippocampus and the medial temporal lobe in Alzheimer disease subjects.
Therefore, functional connectivity measured by RS-fMRI has shown potential as a
biomarker for dementia diagnosis. The observed positive correlation between the newly
defined biomarker of neuronal activity measured by RS-fMRI and the MMSE score
suggest that this biomarker is also related to cognitive function and performance.
Furthermore, the positive association between neuronal activity measured by RS-fMRI
and Aβ1-42provides a direct link to disease pathology.
The new RS-fMRI metric related to brain activity showed different regional
differences between NEC and Alzheimer disease subjects than that observed with FDGPET. Previous studies have found that cerebral blood flow is closely coupled with brain
metabolism,53,54 and that both are decreased in people with Alzheimer’s disease.55-59
Previous studies have also shown that there is an association between the resting brain
activity and resting brain metabolism.60 The strong correlation observed between RSfMRI measured gray matter activity and FDG-PET measured glucose consumption in the
current study is consistent with the notion that glucose metabolism is tightly coupled to
the RS-fMRI measured brain activity. This result is also consistent with a recent study by
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Aiello et. al.61 who showed a voxel-wise relationship between functional connectivity
maps from RS-fMRI and glucose uptake measured by simultaneous FDG-PET in healthy
subjects. Another recent study by Nugent et. al.62 demonstrated that the correlation
between functional connectivity maps derived from RS-fMRI and glucose metabolism
measured by FDG-PET was lower in temporal lobe epilepsy patients compared to control
subjects.
The group differentiation accuracy achieved using the brain activity metric in the
accumbens measured by RS-fMRI was lower than that found when using FDG-PET
measured glucose metabolism in the hippocampus (0.85). However, when combining
hippocampal volume with brain activity from RS-fMRI in the hippocampus, the
classification accuracy increased to 0.80, which is comparable to the FDG-PET results
and significantly greater than using hippocampal volume alone. The specificity achieved
when using the combined MRI-based measurements (0.89) was also greater than that
achieved by FDG-PET and hippocampal volume alone. These results suggest that the
combination of these MRI-based features could help to discriminate between healthy
subjects and people with AD.
This proof of concept study demonstrates that decreased resting-state brain activity is
associated with decreased brain glucose metabolism in mild Alzheimer disease.
Furthermore, we demonstrated group classification based on a first-order textural feature
(standard deviation) of the RS-fMRI neuronal signal. It is noteworthy that when using a
non-linear transformation (square root) of the resting-state signal (data not shown), group
differences were not observed. There are several limitations of the current study that must
be mentioned. First, the sample size was limited by the availability of subjects with both
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ten-minute RS-fMRI data and FDG-PET. Regardless, the new metric was still able to
differentiate between NEC and mild Alzheimer disease groups. Another limitation of this
study is that we did not perform gray atrophy correction for either the RS-fMRI of FDGPET signal changes. Therefore gray matter volume reduction in the hippocampus may
partly explain the reduced RS-fMRI and FDG-PET measured brain activity. However,
Mosconi et. al.63 showed FDG-PET measured hypometabolism in the hippocampus
despite atrophy correction in hippocampus. Gray matter atrophy measurements in the
current study did show significant differences in the hippocampus between the two
groups. However a classification model that included both the hippocampal volume and
RS-fMRI brain activity showed an improved result to classification using either metric
alone. Therefore, including this straightforward measurement of neuronal activity by RSfMRI with existing markers of neurodegeneration may increase the reliability of
detecting Alzheimer’s disease. Future studies will evaluate the potential to identify
people with mild cognitive impairment that progress to AD and whether this metric
shows improvement following treatment.
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Chapter 4: Combining Measures of Gait and Cognition to
Predict Hippocampal Atrophy in Mild Cognitive Impairment
The work presented in this chapter is in preparation for submission for publication.

Samaneh Kazemifar, Manuel Montero-Odasso, and Robert Bartha

4.1 Introduction
Mild cognitive impairment (MCI) is defined as a transitional stage between normal
aging and dementia1 and is clinically characterized by changes over time in distinct
cognitive domains including: memory, executive function, attention, language and
visuospatial skills. MCI is categorized into four types based on the presence of memory
impairment and/or cognitive impairment in single or multiple domains.2,3 MCI subjects
have a higher risk (10-15% per year) of progressing to Alzheimer’s disease compared
with age-matched controls.4 Previous cross sectional group studies have shown reduced
hippocampal volume,5,6 worse gait performance,7-9 as well as worse cognitive10,11 and
memory performance in people with MCI. However it is well known that some people
with MCI remain stable or improve over time, while others decline.

Hippocampal

atrophy in particular has evolved into an objective biomarker associated with cognitive
decline and dementia.12,13 The overall objective of this study was to determine whether
measures of gait and cognitive performance could be combined to predict hippocampal
atrophy in people with MCI.
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There is a strong rationale to combine measures of cognition and gait to predict
progression to dementia. Cognitive decline has been associated with a risk of falls,14-16
which may also involve physiological dysfunction including impaired balance, slowed
reaction time, muscular weakness and gait decline.17,18 Executive function is an important
component of cognition and is referred to as the ability to control, remember, monitor,
and organize information.19 Impairment of executive function with age has been
correlated with changes in the frontal lobe and is consistently associated with an
increased risk of falls.16 In addition, impairment in executive function is associated with
poor balance, gait, and decline in physical performance.20,21
Assessment of gait can include a single gait task or a dual gait task, which
involves combined walking and simultaneous performance of a cognitive task. Previous
studies in MCI subjects have also shown decrease gait velocity8,9 and increased stride
time variability22 in gait analyses. Recently, a dual task gait analysis showed increased
gait variability and decreased walking speed in MCI subjects compared to healthy
controls when the dual task complexity increased.23 Similarly, Muir et. al.24 showed
increased gait variability and decreased walking speed in AD subjects and people with
MCI compared to a healthy group during dual task.
There is also a potential relationship between specific cognitive domains and gait
measurements. For example, there was an association between decreased gait speed and
working memory in MCI subjects;7 and an inverse correlation between gait variability
and executive performance in older adults25 and subjects with AD.26 Dual task
performance has also been associated with decreased executive function.27 Therefore,
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single and dual-task gait measurements can be considered a motor signature of MCI and
may be a biomarker of cognitive decline.28
Previous studies have also evaluated structural brain changes associated with gait and
cognitive impairment in older adults and MCI subjects. Regional brain atrophy of the
hippocampus was associated with decreased stride length in older adults29 and correlated
with increased stride time variability.30 In addition, Palm et. al.31 found that ventricle
enlargement was associated with decreased gait speed and cognitive decline in older
adults. Another study showed that the temporal horn of the ventricle increased with stride
time variability in older adults32 and that the primary motor cortex volume was correlated
with gait performance in MCI subjects.33 Other regions of cortical atrophy have also been
associated with gait decline including the prefrontal cortex, which was associated with
decreased gait velocity,34 and the sensorimotor and frontoparietal cortex, which were
associated with decreased stride length.35
In summary, there are established associations between cognition and gait, brain
atrophy and gait, as well as brain atrophy and cognition. In addition, hippocampal
atrophy is an established biomarker of Alzheimer’s disease progression. However it is
unknown whether measure of gait performance or cognition can predict hippocampal
atrophy in people with MCI. Therefore, the objective of this study was to determine
whether combined measures of gait and cognition could predict hippocampal atrophy
over 18 months in people with amnestic MCI.
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4.2 Methods
4.2.1 Study population
The ‘Gait and Brain Study’ in London, Ontario, Canada was approved by the
University of Western Ontario Health Sciences Research Ethics Board. Cross-sectional
and longitudinal neuropsychological tests, gait assessments, and magnetic resonance
(MR) images were obtained from 22 people with MCI who were 65 years and older.
Subjects were excluded if they were diagnosed with another type of neurologic disorder
(e.g. Parkinson disease), or a medical or psychiatric disorder (e.g. stroke and depression),
were taking medication (e.g. benzodiazepines) that might affect cognition, had a
musculoskeletal disorder (e.g. osteoarthritis) or a disability that prevented walking
independently, or had a hip/knee replacement that affected gait performance. Participants
were also excluded if they had metal implants or claustrophobia that were incompatible
with 3T MRI, and were not fluent in English. Complete data sets for 22 MCI subjects
were available at both baseline and 18 month and were used for this study.

4.2.2 Cognitive Measures
Global cognition was assessed using the mini mental state examination36 (MMSE)
and the Montreal cognitive assessment10 (MoCA). All participants were also assessed
using a battery of neuropsychological tests to evaluate different cognitive domains:
episodic

memory

(Rey

Auditory

Verbal

learning

Test37

(RAVLT)),

verbal

comprehension and working memory (Letter numbering test38), executive function (Trail
Making Test B39,40), and attention and processing speed (Trail Making Test A,40 Digit
Span Test forward and backward41). We used standard diagnostic criteria for amnestic
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MCI (impairment in episodic memory without other cognitive impairment) and MCI
(impairment only in other cognitive domains). To increase the specificity of diagnosis a
cut off of 1.5 SD below the age-adjusted means was used on cognitive domains (on at
least two neuropsychological tests in one of the five cognitive areas). Subjects with MCI
did not meet the diagnostic criteria for Alzheimer disease. Cognitive testing was
performed at baseline and repeated at six-month intervals until 18 months.

4.2.3 Gait Analysis
Gait performance was assessed using a computerized walkway with embedded
®

pressure sensors (GAITRite , 600 x 64 x 1 cm, active electronic surface area 792 x 610
cm, with a total of 29952 pressure sensors, scanning frequency 60 Hz, software version
®

3.8, CIR Systems). The GAITRite

system is a reliable tool for gait analysis that has

been validated for several gait protocols including for assessments of gait velocity and
variability.42 The single-task and dual task trials were performed in random order to
minimize the error of learning. To avoid acceleration and deceleration errors,
participant’s started 1m before reaching the electronic walkway and ended their walk 1m
beyond it, consistent with validated protocols.42,43 During single-task conditions,
participants walked at their usual pace. In dual-task conditions, participants walked in
combination with three different cognitive tasks performed aloud: counting backwards by
1 from 100, subtracting serial seven from 100, and naming animals. Both simple and dual
task conditions were used to evaluate the following gain parameters: gait velocity (cm/s),
gait stride time (s), gait stride time variability (a.u.) (standard deviation of stride
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time/mean stride time), step time (s), stride length, step length, double support time (s),
swing time (s), stride width, step width, stride velocity, cadence, step time coefficient of
variation, stride length coefficient of variation, step length coefficient of variation, double
support time coefficient of variation, swing time coefficient of variation, stride width
coefficient of variation, step width coefficient of variation, and stride velocity coefficient
of variation. Gait assessment occurred at baseline and again at 18 months.

4.2.4 MRI
MR images were acquired to measure hippocampal atrophy using a 3T Magnetom
Prisma MRI scanner with a Siemens (Erlangen, Germany) 64-channel head/neck coil.
Structural T1-weighted images were obtained using a sagittal 3D magnetization-prepared
rapid acquisition with a gradient echo (MP-RAGE) sequence: flip angle= 9°, TE= 2.9ms,
TR= 2300ms, TI= 900 ms, FOV= 256 x 240 mm2, matrix, 256x240 pixel size,
1mm×1mm×1.2mm; 160 slices, total duration= 9.25 min). All imaging was performed at
baseline and repeated at 18 months.

4.2.5 Medial Temporal Lobe Atrophy
The 3D T1-weighted MR images were used to segment the medial temporal lobe
(MTL) at baseline and 18 month follow-up using the in-house software called EXACT as
previously described in detail44 and found in Chapter 2 of this thesis. The MTL volume
included primarily the hippocampus, the amygdala, fibers associated with the amygdala,
and the parahippocampal gyrus. The FreeSurfer software (version 5.3.0) was also used to
segment subcortical regions including the hippocampus, the lateral ventricle, and the
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temporal horn of the lateral ventricle. FreeSurfer (http://surfer.nmr.mgh.harvard.edu/) is
free automated software for processing and analyzing human brain structural and
functional MR images. Briefly, the volumetric processing included removal of non-brain
tissue,45 Talairach transformation, and segmentation of the subcortical white matter and
deep gray matter volumetric structures.46,47 All brain volumes were normalized to the
intracranial volume obtained with FreeSurfer to obtain a volume ratio (VR). In addition,
the change in volume (ΔV) over 18 months was also measured for each structure.

4.2.6 Feature extraction
An overview of the feature extraction method is shown in Figure 4.1. In this study,
all measurements including gait, neuropsychological, and brain volumetrics are presented
in an n x m data matrix, where n is the number of subjects and m is the number of
measurements. A principle component analysis48,49 (PCA) was used to extract principle
components (PCs) or eigenvectors that explained the maximum variance of the data
matrix. We selected the PCs that had eigenvalues greater than one as previously
described.50 Then, the data matrix (n x m) was multiplied with PCs (m x v) to produce
projection data (n x v), where v is the number of eigenvalues> 1. A machine learning
method was then applied to predict hippocampal atrophy (two groups) using the
projection data from the PCA. Here, the subjects were divided into two groups (stable
and decliner) based on the change in volume (ΔV) of the MTL measured by EXACT.
Using this definition, 14 subjects were considered stable and 8 subjects showed MTL
atrophy.
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Figure 4.1 Schematic of the analysis pipeline
Variables include gait, neuropsychological, and anatomical measurements at baseline and over 18
months. The PCA method is used for feature extraction and is followed by the SVM classifier.

PCA was performed in SPSS (Statistical Package for the Social Sciences, version 24).
Table 4.1 shows the demographic information for all subjects and includes a summary of
the anatomical, gait, and neuropsychological measurements at baseline and 18 months.
Two separate analyses were performed. The first analysis incorporated only baseline
measurements to assess prediction ability. The second analysis incorporated only changes
in measurements over 18 months to assess associations. In the analysis of the baseline
measurements, the input data (22 subjects x m variables) included two classes: the stable
MCI group (14 participants) and the decliner MCI group (8 participants). All m gait,
neuropsychological, and MRI measures were also included. For the analysis of the
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changes over 18months the input data (22 subjects x m variables) incorporated only the
neuropsychological and gait measurements. The PCA extracted the most influential
components associated with the baseline and 18-month change measurements. The
projection of the PCA (22 subjects x v) using the baseline data and the projection of the
PCA (22 subjects x v) using the 18 months changes were passed into the support vector
machine.
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Table 4.1 Subject demographic
Neuropsychological, gait, and anatomical measurements are provided for all participants.
Hippocampus, temporal horn and lateral ventricle volumes are normalized to intracranial volume.
The first value shows the mean and the parentheses show the standard error of mean (SEM). *P
value<0.05 (paired, two tailed)

MCI

MCI

Baseline
22
73.0 (1.2)
13.2 (0.5)
6/22

18 month
22
74.5 (1.2)
13.2 (0.5)
6/22

Neuropsychological Test Scores
MMSE
MOCA
Trail A
Trail B
RAVLT
Letter Numbering
Digit Forward
Digit Backward

29.0 (0.3)
25.0 (0.6)
41.7 (3.6)
110.2 (14.3)
5.3 (0.6)
8.2 (0.5)
11.1 (0.4)
7.4 (0.5)

28.0 (0.4)
25.1 (0.5)
37.1 (3.3)
111.0 (17.4)
6.5 (0.5)
8.3 (0.6)
11.0 (0.4)
7.1 (0.6)

0.09
0.7
0.1
0.9
0.04*
0.9
0.8
0.6

Single Task Gait Measures
Usual Gait Velocity (cm/s)
Usual Gait Stride Time (ms)
Usual Gait Stride Time Variability (a.u.)

117.1 (4.4)
1142.3 (24.6)
2.4 (0.3)

115.1 (4.0)
1128.2 (21.3)
4.2 (1.4)

0.6
0.6
0.2

Dual Task Gait Measures
Counting Gait Velocity (cm/s)
Counting Gait Stride Time (ms)
Counting Gait Stride Time Variability (a.u.)
Serial 7s Gait Velocity (cm/s)
Serial 7s Gait Stride Time (ms)
Serial 7s Gait Stride Time Variability (a.u.)
Naming Animal Gait Velocity (cm/s)
Naming Animal Gait Stride Time (ms)
Naming Animal Gait Stride Time Variability (a.u.)

114.1 (6.0)
1200.4 (36.8)
3.3 (0.4)
99.2 (7.4)
1365.8 (60.0)
6.3 (1.1)
103.5 (6.0)
1291.0 (41.5)
3.7 (0.5)

108.6 (4.6)
1193.3 (23.1)
2.8 (0.3)
96.8 (5.3)
1315.3 (54.3)
4.5 (0.8)
99.1 (5.5)
1281.5 (47.1)
3.1 (0.2)

0.3
0.8
0.3
0.7
0.4
0.2
0.4
0.8
0.3

0.0049 (0.0001)
0.001 (0.0001)
0.02 (0.002)

0.0048 (0.0001)
0.001 (0.0001)
0.02 (0.002)

0.6
0.5
0.6

Time
N
Age (years)
Education (years)
Sex (Female)

MRI Measures
Hippocampus Volume Ratio
Temporal Horn Ventricle Volume Ratio
Lateral Ventricle Volume Ratio

P
value
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4.2.7 Support vector machine
The support vector machine (SVM), a classifier that finds a separating hyperplane
between two classes (groups), was performed in Matlab (version R2010a, with linear
kernel function, and least square method).51-53 We used the projection baseline data (22
subjects x v) to discriminate stable and decliner classes (groups). Similarly, the projection
18 month change data (22 subjects x v) were used to classify stable and decliner classes
(groups). In this study, the leave one out test (LOOT) cross-validation technique was
performed to train a given labeled training set and unused data were validated to identify
its label. The training and testing phase were preformed individually for baseline and 18
months change measurements. To evaluate the performance of the SVM classifier, the
accuracy, sensitivity, and specificity (statistical measurements) were calculated. Here,
true positive indicates decliners that were correctly identified as decliner class. False
positive is the number of stable subjects incorrectly identified as the decliner class. True
negative is the number of stable subjects correctly identified as stable subjects. False
negative is the number of decliners incorrectly identified as stable subjects. Therefore,
accuracy refers to the proportion of true results (both true positive and true negative) over
the total number of subjects. Sensitivity indicates the proportion of subjects correctly
detected as decliners (number of true positive over number of true positive and number of
false negative). Specificity shows the proportion of subjects correctly identified as stable
(number of true negative over number of true negative and number of false positive).
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4.2.8 Statistical analysis
Prism GraphPad (Prism, version 6.00; GraphPad Software, San Diego, CA) and Matlab
toolbox (version R2010a) were used for the statistical analyses. A one-way ANOVA was
used to compare cognitive, gait, and neuroimaging measurements between the stable and
decliner MCI groups (p<0.05 considered significant). Individual measurements were also
compared at baseline and 18 months follow-up using a repeated measures t-test with two
tailed. Individual measurements between the Decliner and Stable MCI groups were also
compared using ANOVA with Bonferroni correction. Associations between cognitive
tests and imaging measures were evaluated by linear regression with Pearson correlation
coefficients with p <0.05 considered significant.

4.3 Results
Table 4.1 summarizes subject demographic information as well as summative
measures at baseline and 18 month follow-up. Although gait measurements consisted of a
total of 74 variables (Table 4.8) only the twelve most common are reported in Table 4.1
and included in the one-way ANOVA comparison. The one-way ANOVA indicated that
was a significant overall difference between baseline and 18 months follow-up when
incorporating the anatomical, neuropsychological, and gait measurements (p<0.0001).
However follow-up repeated measures comparisons (Bonferroni’s corrected for 23
comparisons) failed to identify specific variables that were different between the two
groups. Interestingly, there was a significant correlation between the change in MTL
volume and change in RAVLT over 18 months across all subjects (Figure 4.2). There
were no other correlations between changes in MTL volume and cognitive measures.
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Figure 4.2 Association between change in RAVLT and the change in MTL volume
over 18 months
(r= 0.53, p=0.01) Subjects were considered stable or in decline based on the sign of the MTL
volume changes. Data for 19 subjects is included because 3 subjects did not have RAVLT at one
time point.

Tables 4.2 and 4.3 summarize the demographic information as well as important gait,
neuropsychological, and anatomical measurements for the stable and decliner groups at
baseline and 18 months. A one-way ANOVA indicated that there was a significant
difference between the stable and decliner groups in all measurements at baseline
(p<0.0001) and in the changes observed over 18 months (p<0.0001). However,
examining individual measurements, there were no significant differences between these
groups at baseline or over 18 month following Bonferroni correction for 23 comparisons.
Tables 4.4 and 4.5 show the accuracy, sensitivity, and specificity obtained when using the
anatomical, neuropsychological, and gait measurements or combinations of these
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measurements at baseline and after 18 months. In the analysis of the baseline data, gait
measures had the highest overall accuracy (0.74), sensitivity (0.66), and specificity (0.75)
for

identifying

hippocampal

atrophy.

Adding

baseline

brain

volumetrics

or

neuropsychological assessments did not improve the overall accuracy, sensitivity, and
specificity of the gait measurements. While, in the 18 months change analysis, the
neuropsychological measurements achieved the highest overall accuracy (0.72),
sensitivity (0.32), and specificity (0.89). The addition of gait measurements did not
improve the overall accuracy, sensitivity, and specificity (Table 4.5).
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Table 4.2 Subject demographics of the two groups at baseline
The neuropsychological, gait, and anatomical measurements at baseline are shown in the
8decliner and 14 stable subjects. The first value shows the mean and the parentheses show the
standard error of the mean (SEM). *P value<0.05 (unpaired, two tailed)

Decliner MCI

Stable MCI

Baseline
8
70.8 (1.5)
14.2 (1.0)
25%

Baseline
14
74.1 (1.6)
12.6 (0.6)
29%

Neuropsychological Test Scores
MMSE
MOCA
Trail A
Trail B
RAVLT
Letter Numbering
Digit Forward
Digit Backward

29.1 (0.5)
25.6 (0.9)
47.0 (8.9)
122.3 (37.1)
5.6 (1.6)
7.5 (0.6)
10.5 (0.7)
6.5 (0.8)

28.8 (0.4)
24.5 (0.8)
38.7 (2.7)
103.3 (8.8)
5.1 (0.6)
8.7 (0.7)
11.5 (0.5)
7.9 (0.6)

0.6
0.4
0.2
0.5
0.7
0.2
0.2
0.05

Single Task Gait Measures
Usual Gait Velocity (cm/s)
Usual Gait Stride Time (ms)
Usual Gait Stride Time Variability (a.u.)

123.3 (8.9)
1125.2 (57.2)
2.7 (0.6)

113.6 (4.6)
1152.3 (22.0)
2.3 (0.3)

0.3
0.6
0.6

Dual Task Gait Measures
Counting Gait Velocity (cm/s)
Counting Gait Stride Time (ms)
Counting Gait Stride Time Variability (a.u.)
Serial 7s Gait Velocity (cm/s)
Serial 7s Gait Stride Time (ms)
Serial 7s Gait Stride Time Variability (a.u.)
Naming Animal Gait Velocity (cm/s)
Naming Animal Gait Stride Time (ms)
Naming Animal Gait Stride Time Variability (a.u.)

122.6 (11.1)
1157.8 (60.2)
3.0 (0.4)
105.9 (16.1)
1367.3 (132.4)
5.3 (1.6)
112.7 (12.0)
1225.0 (71.2)
3.2 (0.8)

109.2 (6.8)
1224.7 (46.1)
3.5 (0.6)
95.3 (7.3)
1364.9 (60.0)
6.9 (1.4)
98.1 (6.2)
1328.7 (49.3)
4.0 (0.7)

0.2
0.3
0.5
0.5
0.9
0.4
0.2
0.2
0.5

MRI variables
Hippocampus Volume Ratio
Temporal Horn Ventricle Volume Ratio
Lateral Ventricle Volume Ratio

0.0048 (0.0001)
0.001 (0.0002)
0.02 (0.003)

0.0049 (0.0002)
0.0009 (0.0001)
0.02 (0.003)

0.7
0.5
0.2

Time
N
Age (years)
Education (years)
Sex (% Female)

P
value
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Table 4.3 Subject demographics of the two groups showing 18-month changes
The changes in the neuropsychological, gait, and anatomical biomarkers are compared for
the8decliner and 14 stable subjects. First value shows the mean and parentheses show the
standard error of the mean (SEM). *P value<0.05 (unpaired, two tailed)

Decliner MCI

Stable MCI

P
Value

Time
N

Δ18 months
8

Δ18 months
14

Neuropsychological Test Scores
MMSE Changes
MOCA Changes
Trail A Changes
Trail B Changes
RAVLT Changes
Letter Numbering Changes
Digit Forward Changes
Digit Backward Changes

-1.0 (0.6)
-0.1 (0.9)
-10.1 (4.7)
16.0 (18.3)
1.3 (0.8)
1.3 (0.8)
-0.2 (0.6)
0.7 (0.7)

-0.8 (0.6)
0.4 (0.6)
-1.4 (1.8)
-8.0 (8.4)
1.1 (0.8)
-0.7 (0.4)
-0.07 (0.5)
-0.8 (0.4)

0.8
0.6
0.03*
0.1
0.8
0.02*
0.8
0.054

Single Task Gait Measures
Usual Gait Velocity (cm/s) Changes
Usual Gait Stride Time (ms) Changes
Usual Gait Stride Time Variability (a.u.) Changes

-6.0 (8.0)
-4.2 (48.2)
-0.2 (0.8)

0.2 (3.4)
-19.8 (28.1)
2.8 (2.3)

0.4
0.7
0.3

Dual Task Gait Measures
Counting Gait Velocity (cm/s) Changes
Counting Gait Stride Time (ms) Changes
Counting Gait Stride Time Variability (a.u.) Changes
Serial 7s Gait Velocity (cm/s) Changes
Serial 7s Gait Stride Time (s) Changes
Serial 7s Gait Stride Time Variability (a.u.) Changes
Naming Animal Gait Velocity (cm/s) Changes
Naming Animal Gait Stride Time (ms) Changes
Naming Animal Gait Stride Time Variability Changes (a.u.)

-10.1 (8.3)
-10.8 (34.2)
-0.1 (0.7)
-3.1 (10.5)
-101.0 (109.6)
-1.0 (2.0)
-7.6 (6.2)
-16.2 (36.4)
-0.2 (1.2)

-2.7 (4.6)
-4.8 (44.6)
-0.8 (0.6)
-2.0 (5.1)
-21.0 (65.1)
-2.3 (1.0)
-2.4 (4.0)
-5.5 (44.3)
-1.0 (0.7)

0.4
0.9
0.5
0.9
0.5
0.5
0.4
0.8
0.5

MRI variables
Hippocampus Volume Changes (mm3)
Lateral Ventricle Volume Changes (mm3)
Temporal Horn Ventricle Volume Changes (mm3)

-201.3 (92.3)
934.1 (500.6)
92.7 (111.6)

3.9 (181.6)
3590.6 (991.3)
198.8 (79.2)

0.4
0.06
0.4
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Table 4.4 Summary of accuracy, sensitivity, and specificity for the stable and
decliner groups based on the baseline measurements after PCA projection

SVM_ linear Baseline

# PCs

Accuracy

Sensitivity

Specificity

Neuropsychological

2

0.70

0

1

Gait

12

0.74

0.66

0.75

MRI

1

0.63

0

0.86

Gait + Neuropsychological

13

0.60

0.27

0.70

Gait + MRI

13

0.70

0. 43

0.85

Neuropsychological + MRI

4

0.73

0

1

Gait + Neuropsychological + MRI

14

0.60

0.30

0.76

Table 4.5 Summary of the accuracy, sensitivity, and specificity for the stable and
decliner groups based on the changes in measurements over 18 months after PCA
projection

SVM_ linear Δ18 months

# PCs

Accuracy

Sensitivity

Specificity

Neuropsychological

4

0.72

0.32

0.89

Gait

12

0.64

0.30

0.73

Gait + Neuropsychological

15

0.69

0.30

0.81
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To identify the measurements that were most influential in the PCA, a heat map was
used to show the coefficients for each variable in the PCs that had eigenvalues greater
than one. Figure 4.3 shows the heat map associated with the gait measurements at
baseline, while Figure 4.4 shows the heat map associated with the neuropsychological
measures over time. These are shown because these measures were found to have the
greatest accuracy, sensitivity, and specificity. The color in the heat map shows the
contribution weight of the measurement in the principle component. A hot color shows a
higher coefficient and a cold color illustrates a lower coefficient. Each coefficient shows
the proportion of the eigenvalue corresponding to each principle component
(eigenvalue= (coefficent ! )). The proportion of the variance is accounted for each PC by
var =

eigenvalue

#  variables. Therefore, the first PC includes the maximum proportion

of variance in the data and the accumulation of all variance is equal to one. Table 4.6
provides the ten highest numerical coefficients associated with the first PC in the heat
map shown in Figure 4.3, while Table 4.7 provides the 4 highest numerical coefficients
associated with the first PC in the heat map shown in Figure 4.4. In the baseline analysis,
the gait velocity, and stride velocity during single and dual tasks were the most important
measurements. Examining changes over 18 months, the digit span test forward and
backward tests had the highest predictive values.
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Figure 4.3 Heat map to identify the most important baseline measurements
contributing to each principle component (PC)
Each row indicates a different measurement with the measurement number identified on the left
corresponding to the measurement numbers in Table 4.8. The colors indicate the coefficient and
provide the contribution weight of the measurement in each principle component.
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Figure 4.4 Heat map to identify the most important 18 months change
measurements contributing to each principle component (PC)
Each row indicates a different measurement with the measurement number identified on the left
corresponding to the measurement numbers in Table 4.9. The colors indicate the coefficient and
provide the contribution weight of the measurement in each principle component.
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Table 4.6 Predictive variables of gait measurements to distinguish between stable
and decliner groups in overall 22 subjects based on baseline values
The coefficient shows the contribution weight of the variable in first principle component.

Dominant Variables

Coefficient

Single gait variables
Usual gait velocity
Stride velocity

-0.88
-0.88

Dual gait variables
Counting gait velocity
Counting gait stride time
Counting stride velocity
Counting cadence

-0.93
0.82
-0.93
-0.84

Serial 7s velocity
Serial 7 stride velocity
Serial 7 cadence

-0.95
-0.95
-0.81

Naming animals velocity
Naming animals stride velocity

-0.92
-0.92

Table 4.7 Predictive variables of neuropsychological measurements to identify stable
and decliner groups in overall 22 subjects based on 18 months change values
The coefficient shows the contribution weight of variable in first principle component.

Dominant Variables
Neuropsychological
MMSE
Trail A
Trail B
Digit span test backward
Digit span test forward

Coefficient
-0.41
-0.44
0.34
0.76
0.72
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4.4 Discussion
In this study, subjects with MCI were divided into two groups (stable and declining)
based on MTL volume changes over 18 months. When incorporating all anatomical, gait,
and neuropsychological measurements there was an overall significant difference
between those identified as stable and those that declined. However, when comparing
individual measurements between both groups, no significant differences were found
following Bonferroni correction. The use of baseline gait measurements provided the
greatest prediction accuracy of hippocampal atrophy over 18 months. Surprisingly,
combining gait measurements with baseline neuropsychological measurements and brain
volumetrics did not improve prediction accuracy. A potential explanation is that gait can
be more sensitive to brain changes that cognitive testing in early stages of decline.54 This
is supported by epidemiological evidence that shows that slowing gait precede cognitive
decline in cognitively healthy individuals who progress to MCI.55 MTL volume changes
were correlated with changes in the RAVLT. The significant association between
changes in MTL volume and changes in RAVLT score is consistent with previous cross
sectional studies.56,57 Since the RAVLT is an indicator of memory,58,59 it is expected to
correlate strongly with hippocampal volume.
PCA is a statistical technique used to reduce the number of dimensions without
incurring a loss of information. To identify the most important measurements, the PCA
method was applied to all baseline measurements and the changes in these measurements
over 18 months. Using this approach, the baseline gait velocity and stride velocity during
single and dual task had higher eigenvalue coefficients compared to other measures
indicating that these measures explain more of the data variability than other measures.
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This result is consistent with the finding that dysfunction of gait particularly in dual tasks
co-occurs with cognitive functional decline in older adults even in the early stages of
aging.7,54 Also, it has been suggested that dual task gait variables can be used as early
markers for MCI diagnosis.60
Following the PCA, the SVM classifier was applied to predict hippocampal atrophy
using the projection data of the PCA. The baseline gait measures had the highest
accuracy (0.74), sensitivity (0.66), and specificity (0.75) for predicting hippocampal
atrophy. When examining changes over 18 months, the neuropsychological
measurements achieved the high accuracy (0.72), sensitivity (0.32), and specificity
(0.89). The changes over 18 months in the digit span test forward and backward had the
greatest predictive values. Surprisingly, combining gait, neuropsychological, and even
imaging measurements did not improve this classification.

Although there are no

previous studies that combine measures of gait and neuropsychological testing to predict
hippocampal atrophy, several other studies have examined the use of imaging and CSF
measurements to improve classification accuracy between two groups. For example,
Zhang et. al.61 used MRI, PET neuroimaging, and CSF measurements to classify between
healthy, MCI and Alzheimer disease groups using data obtained from the ADNI database.
They found high accuracy, sensitivity and specificity in classification between the healthy
and Alzheimer disease groups when MRI, PET and CSF biomarkers were used. Another
previous study62 used four groups including healthy, early MCI, late MCI and AD groups
from the ADNI database to measure cortical and subcortical MRI volumes and
neuropsychological tests. They found the accuracy was 0.70 to distinguish early MCI
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and late MCI using a combination of all variables; while it were 0.63 and 0.68 using
neuropsychological tests and MRI variables.
This study is unique in that we used hippocampal atrophy to classify subjects into
stable and declining rather than neuropsychological test scores. However, there are
several limitations to this preliminary study that must be considered. The first is the
small sample size, particularly in the group that showed hippocampal volume atrophy. A
future study should replicate these results in a larger sample. Second, the changes
observed in hippocampal volume were small, even over 18 months. Some subjects
increased slightly in volume, while others decreased. Overall, on average there was no
change in this group. This observation suggests that a longer follow-up time may be
needed to accurately determine which subjects are in decline.
In conclusion, this study provides preliminary evidence of gait impairment in people
with mild cognitive impairment who proceed to have hippocampal atrophy within 18
months of follow-up. The results provide a rationale to suggest that gait analysis could
help to predict future hippocampal atrophy in people at risk to progress to dementia.
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Table 4.8 Abbreviation: The number corresponds to the variable in Figure 4.2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

Usual	
  Gait	
  Velocity
Usual	
  gait	
  stride	
  time
Usual	
  gait	
  stride	
  time	
  variability
Step	
  time
Stride	
  length
Step	
  length
Double	
  Support	
  Time
Swing	
  Time
Stride	
  Width
Stride	
  Velocity
Cadence
Step	
  time	
  coefficient	
  of	
  variation
Stride	
  length	
  coefficient	
  of	
  variation
Step	
  length	
  coefficient	
  of	
  variation
Double	
  support	
  time	
  coefficient	
  of	
  variation
Swing	
  time	
  coefficient	
  of	
  variation
Stride	
  width	
  coefficient	
  of	
  variation
Stride	
  velocity	
  coefficient	
  of	
  variation
Counting	
  gait	
  velocity
Counting	
  gait	
  stride	
  time
Counting	
  gait	
  stride	
  time	
  variability
Counting	
  Step	
  time
Counting	
  Stride	
  length
Counting	
  Step	
  length
Counting	
  Double	
  Support	
  Time
Counting	
  Swing	
  Time
Counting	
  Stride	
  Width
Counting	
  Stride	
  Velocity
Counting	
  Cadence
Counting	
  Step	
  time	
  coefficient	
  of	
  variation
	
  Counting	
  Stride	
  length	
  coefficient	
  of	
  variation
Counting	
  Step	
  length	
  coefficient	
  of	
  variation
Counting	
  Double	
  support	
  time	
  coefficient	
  of	
  variation
Counting	
  Swing	
  time	
  coefficient	
  of	
  variation
Counting	
  Stride	
  width	
  coefficient	
  of	
  variation
Counting	
  Stride	
  velocity	
  coefficient	
  of	
  variation
Counting	
  back	
  total	
  number
Serial	
  7s	
  velocity
Serial	
  7s	
  stride	
  time
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40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74

Serial	
  7s	
  stride	
  time	
  variability
Serial	
  7	
  Step	
  time
Serial	
  7	
  Stride	
  length
Serial	
  7	
  Step	
  length
Serial	
  7	
  Double	
  Support	
  Time
Serial	
  7	
  Swing	
  Time
Serial	
  7	
  Stride	
  Width
Serial	
  7	
  Stride	
  Velocity
Serial	
  7	
  Cadence
Serial	
  7	
  Step	
  time	
  coefficient	
  of	
  variation
Serial	
  7	
  Stride	
  length	
  coefficient	
  of	
  variation
Serial	
  7	
  Step	
  length	
  coefficient	
  of	
  variation
Serial	
  7	
  Double	
  support	
  time	
  coefficient	
  of	
  variation
Serial	
  7	
  Swing	
  time	
  coefficient	
  of	
  variation
Serial	
  7	
  Stride	
  width	
  coefficient	
  of	
  variation
Serial	
  7	
  Stride	
  velocity	
  coefficient	
  of	
  variation
Total	
  numbers	
  counted	
  backwards	
  by	
  7
Naming	
  animals	
  velocity
Naming	
  animals	
  stride	
  time
Naming	
  animals	
  gait	
  stride	
  time	
  variability
Naming	
  animals	
  Step	
  time
Naming	
  animals	
  Stride	
  length
Naming	
  animals	
  Step	
  length
Naming	
  animals	
  Double	
  Support	
  Time
Naming	
  animals	
  Swing	
  Time
Naming	
  animals	
  Stride	
  Width
Naming	
  animals	
  Stride	
  Velocity
Naming	
  animals	
  Cadence
Naming	
  animals	
  Step	
  time	
  coefficient	
  of	
  variation
Naming	
  animals	
  Stride	
  length	
  coefficient	
  of	
  variation
Naming	
  animals	
  Step	
  length	
  coefficient	
  of	
  variation
Naming	
  animals	
  Double	
  support	
  time	
  coefficient	
  of	
  variation
Naming	
  animals	
  Swing	
  time	
  coefficient	
  of	
  variation
Naming	
  animals	
  Stride	
  width	
  coefficient	
  of	
  variation
Naming	
  Animals	
  Stride	
  velocity	
  coefficient	
  of	
  variation	
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Table 4.9 Abbreviation: The number corresponds to the variable in Figure 4.3
1
2
3
4
5
6
7

MMSE
MoCA
Trail	
  A
Trail	
  B
Digit	
  Forward
Digit	
  Backward
Letter	
  Numbering
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CHAPTER 5: Conclusion and Future work
This chapter includes an overview of the thesis, a summary of the main contributions,
and provides suggestions for further investigation and development.

5.1 Overview and Summary
The limitations of current tools for the pre-symptomatic diagnosis and monitoring of
disease progression for Alzheimer disease (AD) provided the motivation for developing
more sensitive biomarkers. Such biomarkers could be used for early detection of AD and
other related dementias, as well as monitoring disease progression and response to new
treatments. The monitoring of treatment effects is an area of particular need to hasten the
development of more effective drugs that slow the progression of the disease.
The preclinical or pre-symptomatic stage of AD is associated with pathological
changes that begin 10-15 years before synaptic or neuronal loss result in cognitive
decline and dementia. Therefore, new candidate drugs will be needed to intervene at an
early stage of the disease to prevent brain damage and subsequent dementia. Currently,
AD is diagnosed base on the results of a clinical examination and cognitive testing, but a
clinical diagnosis can result in misclassification because a definitive biomarkers does not
exist.1 Furthermore, clinical examination cannot detect pre-symptomatic AD and cannot
measure the rate of disease progression.
It is challenging to develop biomarkers for presymptomatic AD because changes in
the brain are subtle. The ideal biomarker should reveal AD pathology, be reliable, be easy
to measure, and be relatively inexpensive.2 Imaging methods including anatomical MRI,
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PET, and functional MRI, which can assess regional/global structural and functional
impairment have the potential to identify pathological changes associated with AD.
One example of a widely studied anatomical measurement is hippocampal atrophy,
which has been associated with memory loss in AD subjects.3 This anatomical
assessment could be a suitable biomarker of the transition from normal cognition to mild
cognitive impairment (MCI), and from MCI to AD. Due to inter-individual variation in
the volume of anatomical structures, the change in volume of these structures is likely to
be a more sensitive indicator of Alzheimer disease (AD) progression. Although several
methods are available to measure brain volumes, improvements in speed and automation
are required. We hypothesized that a highly reproducible measure of the change in MTL
(ΔMTL) volume would be a sensitive marker of Alzheimer disease progression. In
Chapter 2 of this thesis, we described a novel, fully automated, fast, and reliable
segmentation method designed to measure the change in MTL volume including
primarily hippocampus over time in the same subject. The novel segmentation approach
presented here combined a multiple atlas-based registration method to define the tissue
region of interest, a level set algorithm to refine the shape of the medial temporal lobe,
and registration of baseline images to follow up images to increase measurement
precision. The measured volume change in the MTL is the difference between the
baseline and follow-up volume. The automated segmentation approach developed in this
study represents an expedient atrophy change in tissue (EXACT) measurement of the
brain. Baseline and 24 month 3D T1-weighted images from the Alzheimer Disease
Neuroimaging Initiative (ADNI) were randomly selected for 50 normal elderly controls
(NEC), 50 subjects with mild cognitive impairment (MCI) and 50 subjects with AD to
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test the algorithm. A manual segmentation of the hippocampus showed that the
hippocampus accounts for only about 40% of the total volume of interest included by the
EXACT method. The average hippocampal volume change measured using the EXACT
method was significantly smaller than that measured using the FreeSurfer software
package in NEC (p=0.03), MCI (p=0.001), and AD (p=0.003). However, the EXACT
method showed a significant difference in MTL volume change between all three groups
while the FreeSurfer measurements did not detect a difference between the MCI and AD
subject groups. The novel segmentation approach we developed is fully automated and
provides a robust marker of brain atrophy that showed different rates of atrophy over two
years in NEC, MCI, and AD groups. The MTL atrophy measures also correlated with
decline in cognitive performance.
In Chapter 3, the goal was to define a novel biomarker of neuronal activity based on
a first-order textural feature of the resting state functional-MRI (RS-fMRI) signal. The
hypothesis was that the fluctuation of the magnitude of the blood oxygen level dependent
(BOLD) signal as a function of time is related to neuronal activity and therefore would
also correlate with FDG-PET measures of glucose metabolism. Furthermore, we
examined the association between the fluctuation magnitude of the neuronal derived RSfMRI signal and FDG-PET. In this study, after pre-processing the RS-fMRI signal, an
independent component analysis (ICA) method was applied to the RS-fMRI, followed by
template matching to identify neuronal components (NC). A brain activity map was
constructed based on the variation of the RS-fMRI signal from these NC. The
standardized glucose uptake values of several brain regions relative to the cerebellum
(SUVR) were also measured from partial volume corrected FDG-PET images. We
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studied 15 normal elderly controls (NEC) and 15 probable Alzheimer disease (AD)
subjects from the AD Neuroimaging Initiative (ADNI) database. In addition, the mini
mental state examination (MMSE) score, CSF biomarkers including total Tau protein
(Tau), phosphorylated Tau protein (P-Tau) and amyloid-β (Aβ1-42) were obtained for all
subjects. Comparing the AD and NEC groups, the mean brain activity metric was
significantly lower in the accumbens, while the glucose SUVR was significantly lower in
the amygdala and hippocampus. There was also a significant correlation between the
MMSE score and brain activity measured using RS-fMRI in several brain regions.
Similarly there was a significant correlation between CSF Aβ1-42 levels and the RS-fMRI
measured brain activity in several brain regions. We found a pixel-by-pixel association
between the RS-fMRI measured brain activity in gray matter and the rate of glucose
metabolism measured using FDG-PET (r=0.77 ± 0.04 for the NEC group and r=0.73 ±
0.03 for the Alzheimer disease group). This proof of concept study demonstrated that
decreased resting-state brain activity is associated with decreased brain glucose
metabolism in mild Alzheimer disease. We demonstrated differences in brain activity
measured by RS-fMRI in effect establishing this measurement as a new potential
biomarker of Alzheimer’s disease. However, future longitudinal studies will be required
to determine its utility in combination with existing markers of neurodegeneration to
determine whether this measurement has a role in the early detection of Alzheimer’s
disease.
In chapter 4, we examined the relationship between gait and hippocampal atrophy in
people with MCI. There are established associations between cognition and gait, brain
atrophy and gait, as well as brain atrophy and cognition in subjects with MCI. In addition,
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hippocampal atrophy is an established biomarker of Alzheimer’s disease progression.
However it is unknown whether measures of gait performance or cognition can predict
hippocampal atrophy in people with MCI. The purpose of this study was to determine
which combination of measurements could best predict hippocampal atrophy over 18
months

in

people

with

MCI.

We

hypothesized

that

the

combination

of

neuropsychological and gait measurements would provide good predictors of
hippocampal atrophy.
We divided 22 MCI subjects into two groups: a stable group and a decliner group
based on medial temporal lobe (MTL) volume changes measured using the EXACT
method (Chapter 2). This resulted in 14 subjects being classified as stable and 8subjects
being classified as declining. The baseline data matrix consisted of gait measurements,
neuropsychological measurements, and brain volumetrics. A principle component
analysis (PCA) was applied to the data matrix to extract principle components (PCs).We
selected the PCs that had eigenvalues greater than one. Then, the data matrix was
multiplied with the PCs to produce projection data. A machine learning method was then
applied to predict hippocampal atrophy (two groups) using the projection data from the
PCA. A support vector machine (SVM) was used on the projection data to classify
subjects as stable or declining using either baseline measurements or the change in gait
and neuropsychological measurements over 18 months. In the analysis of the baseline
data, gait measures had the highest overall accuracy (0.74), sensitivity (0.66), and
specificity (0.75) for identifying hippocampal atrophy. Adding baseline brain volumetrics
or neuropsychological assessments did not improve the overall accuracy, sensitivity, and
specificity of the gait measurements. While, in the 18 months change analysis, the
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neuropsychological measurements achieved the highest overall accuracy (0.72),
sensitivity (0.32), and specificity (0.89). The addition, the gait measurements did not
improve the overall accuracy, sensitivity, and specificity. In the baseline analysis, the gait
velocity, and stride velocity during single and dual tasks were the most important
measurements. Examining changes over 18 months, the digit span test forward and
backward tests had the highest predictive values. Although there were limitations to this
study to the small sample size, the study highlights to potential value of gait
measurements as a predictor of hippocampal atrophy.
5.2 Recent Developments of Imaging Biomarkers
Imaging biomarkers play an important role in improving our understanding of
Alzheimer disease and its staging. More importantly, biomarkers will improve diagnosis
of the disease in its earliest stages and will be necessary to evaluate the effectiveness of
different therapeutic approaches. In addition to the detection of brain structural atrophy in
AD using MRI and the detection of hypometabolism using FDG-PET, other modalities
have been recently developed that may be more effective in the detection of AD
pathology. These methods include the direct detection of amyloid beta and tau using
PET,4,5 resting state fMRI, and perfusion imaging using MRI.6-8 The success of PET
amyloid β imaging with Pittsburgh compound B (PiB) has translated into the clinical
setting as a promising biomarker. Recently, alternative Aβ tracers have been developed
including Florbetapir or [18F]-AV-45 with half-life of 110 minutes that is more
accessible to imaging sites for the detection of Aβ.9 Several tau radio-ligands (18FTHK5105, 18F-5117, 18F-T807 and 18F-T808) also showed higher binding affinity to tau
in Alzheimer disease compared to healthy controls.10 More advance MRI methods have
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also been developed including the use of resting state functional connectivity (FC) in the
default mode network (DMN). Specifically, declines in FC have been associated with the
early stages of Alzheimer’s disease,11 suggesting that resting-state fMRI may be a
promising biomarker for AD.12 Furthermore, measurements of cerebral blood flow (CBF)
using arterial spin labelling (ASL) perfusion, as part of a MRI protocol may improve the
detection of early Alzheimer’s disease pathology. Decreased CBF in subjects with AD
has been associated with increased amyloid-β load6 and CBF measurement was shown to
predict Aβ accumulation in early MCI subjects.7 Measuring the subfields of the
hippocampus using MRI has also been investigated recently. Several research groups
have developed high-resolution MR sequences to assess the hippocampus in vivo at submillimetre resolution on coronal slices13-15 and incorporated automated segmentation
methods16,17 to delineate hippocampal subfields, a technique that has great potential in the
study of Alzheimer’s disease. Combining multiple imaging modalities will provide the
most complete assessment of brain structure and function as an individual ages, and if
Alzheimer’s disease takes hold.
Advances in high resolution-imaging and segmentation of the brain continue to be
made at a record pace. Hippocampal atrophy has been associated with memory loss in
AD subject for more than two decades.18,19 Manual segmentation of the hippocampus has
significant variation due to different anatomical boundaries of this region.20 However, it
is gold standard in neuroanatomical image segmentation and it is time consuming and
subjective particularly in large data sets. Therefore, an effort has been made to establish a
reference standard of hippocampus volume that can be used to compare different
methodologies with these harmonization initiatives.21-23 Related to the methods presented
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in this thesis, other studies have recently shown that the use of multiple atlases can
improve segmentation reliability compared to single atlas based models.24-26 Each atlas
image is registered to a subject image and label propagation is used to produce multiple
labels of the subject image. Finally, label fusion methods including simple majority vote,
cross-correlation weighted majority vote, and normalized mutual information weighted
majority vote is performed to merge these labels of the subject image. For example,
Nestor et. al.27 used 5 protocols of hippocampus segmentation to find their automated
segmentation method can easily adopt to different hippocampus segmentation definition.
They used affine registration to find highest ranked the anterior commissure–posterior
commissure (AC-PC) atlases (n=100) into the subject image using cross-correlation.
Next, a deformable registration was applied to propagate the atlas hippocampal labels to
the subject image. Finally, non-weighted vote-rule was used to combine the best 15
binary templates into subject image. Therefore, there is improvement room within
multiple–atlas based approach, which may include atlas selection, atlas to target matching
scheme, registration parameters and label fusion strategies. Some multiple-atlas based
approaches use large numbers of manually segmentation atlases that take significant time
for nonlinear registration and perform different label fusion strategies. For example,
Aljabar et. al.24 used 275 atlases with simple majority vote to obtain a Dice index of 0.83
compared with manual segmentation in healthy subjects. Previous studies performed
using 80 atlases26 with simple majority vote and 30 atlases28,29 on healthy controls
obtained overlap measurements of 0.89, 0.88 and 0.82. Barnes et. al.30 showed a Dice
index of 0.86 on healthy controls and AD subjects using 55 atlases. In addition, the patch-
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based label fusion method31 provided a 0.84 overlap measurement in ADNI data using 20
atlases.
Recently, one group (Pipitone et. al.) showed investigated a small number of atlases
(<10) in combination of three label fusion methods (cross-correlation, normalised mutual
information-based weighted label fusion and simple majority vote label fusion). Pipitone
et. al.32 used 9 atlases with label fusion to achieve a Dice index of 0.84 between
automated and manual segmentation of the hippocampus. They found there was not
significant effect between three label fusions while multi-atlas segmentation methods
found the cross-correlation and normalized mutual information based weighted label
fusion improves segmentation reliability compared to simple majority vote label fusion.
In addition, development of segmentation algorithm can be appropriate tool to use in
imaging study. The change in volume of this structure is likely to be a sensitive indicator
of Alzheimer disease (AD) progression. Although several methods are available to
measure brain volumes including FreeSurfer, results show a tendency of this method to
overestimate hippocampus volume. In addition, some approaches often use a large
number of manually segmented atlases that take significant time and expert skill to
generate. In comparison, the fully automated EXACT method developed and described in
this thesis used 8 atlases, which provide improvements in speed compared to methods
that use larger numbers of atlases. Multiple atlas labels were not merged and the bestmatched atlas label was selected using normalized mutual information in region of
interest for each subject image. The rationale for including different groups (NEC, MCI
and AD) in atlas date set was to include more representative morphological variation.
Also, the EXACT didn’t use specific hippocampus definition protocol instead, was
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guided by anatomical structures and refined using clearly identifiable tissue boundaries
observed in T1-weighted images. The method also produced a robust marker of medial
temporal lobe atrophy that was sensitive to different rates of atrophy over two years.
Further comparisons with other methods are needed to determine under what conditions
the EXACT method is preferred.

Functional MRI may provide useful information regarding the functional
connectivity of various brain networks including those involved in memory and other
cognitive domains. BOLD fMRI is an indirect measure of neuronal activity, which
reflects the integrated synaptic activity of neurons through MR signal changes resulting
from changes in blood flow, blood volume, and the blood oxyhemoglobin/
deoxyhemoglobin ratio. In this thesis, a novel measurement of neuronal activity was
generated from resting-state functional magnetic resonance imaging data. This measure
is not a metric of functional connectivity. Rather it is based on the fluctuation of the
blood oxygen level dependent (BOLD) signal over time. This new neuronal activity
marker has some similarities to glucose metabolism measured by FDG-PET. In this
thesis, we illustrated the association between this neuronal activity biomarker and glucose
uptake in healthy elderly and people with Alzheimer’s disease. We also demonstrated for
the first time that the new neuronal activity biomarker could differentiate people with
Alzheimer’s disease and healthy controls. The results presented in this thesis are only the
starting point for the evaluation of this measurement. Although promising, the sensitivity
and specificity must now be compared to other potential biomarkers of disease to assess
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whether this measurement has potential benefits. Such an MRI marker could be easily
adopted due to the wide accessibility and low cost of MRI.

5.3 Conclusions
The overall goal of this thesis was to develop and validate new potential structural
and functional biomarkers of Alzheimer disease (AD) that would improve diagnosis and
predict disease progression. In chapter 2, we showed that a fully automated longitudinal
segmentation method provided a robust marker of brain atrophy that was sensitive to
different rates of atrophy over two years between NEC, MCI, and AD groups.
Furthermore, in Chapter 3our goal was to develop a new biomarker of brain function
based on the fluctuation of the magnitude of the RS-fMRI signal. Using this approach we
found lower brain activity in people with mild Alzheimer disease compared to healthy
subjects. In a pixel-by-pixel analysis of gray matter voxels, this brain activity metric
derived from RS-fMRI was also found to be strongly correlated with glucose metabolism
measured by FDG-PET. The observed positive correlation between the newly defined
biomarker of neuronal activity measured by RS-fMRI and the MMSE score also suggest
that this biomarker was related to cognitive performance. Therefore, including this
straight forward measurement of neuronal activity by RS-fMRI may increase the
reliability of detecting Alzheimer’s disease. Overall, these two chapters showed the
volume changes of the MTL and the neuronal activity measurements from RS-fMRI
could be help improve the detection of AD and monitor progression.
In the final study within this thesis we determinedwhether gait and cognitive
measures could predict or were associated with medial temporal lobe atrophy. Medial
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temporal lobe atrophy over 18 months was evaluated using the novel method developed
in Chapter 2. This study provided preliminary evidence that gait is impaired people with
mild cognitive impairment who proceed to have hippocampal atrophy within 18 months
of measurement. Gait analysis could help to predict future hippocampal atrophy.
5.4 Future Directions
The field of imaging biomarker development continues to advance at a rapid pace.
Measurement of brain atrophy is unlikely to be an early indicator of disease, but will
continue to play an important role in monitoring disease progression and treatment
response. Although the hippocampal / medial temporal lobe region is one of the first
areas that is affected in Alzheimer disease, future work should evaluate the combined use
of multiple regions using the EXACT methodology including other subcortical areas
(amygdala, caudate nucleus). The exact method could also be improved. For example,
only a small number of atlases were used (eight) in the EXACT method. Including more
atlases may further increase the robustness of the technique in cases of extreme
anatomical variability, however would also increase computation time. Optimizing the
number of atlases will be the focus of future work. The number of atlases used can
impact the quality of the final segmentation. Combining information from multiple
regions may increase detection sensitivity, but more importantly, may also improve
ability to differentiate Alzheimer’s disease from other forms of dementia including
Fronto-temporal dementia.
New and more sensitive imaging metrics may allow for earlier detection and
assessment of disease modifying therapies. Continued development of novel imaging
modalities would provide complimentary information to existing methods for early
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detection of AD. The brain activity metric that we developed could be further improved
by improving the registration of the fMRI images to the MR anatomical images.
Furthermore, other features including first and second order statistics and wavelet
coefficients may be useful in for measuring brain activity based on the RS-fMRI signal.
The differentiate performance of different features between mild AD and healthy subjects
could be evaluated in terms of accuracy, sensitivity and specificity. Resting state fMRI
has provided new insights related to the functional architecture of the brain in other brain
disorders including epilepsy, schizophrenia, and depression. It would be interesting to
apply new biomarker of brain activity to these other clinical populations.
Definitive diagnosis of AD can only be made post-mortem from brain tissue.
Therefore, determining the disease severity various stages including early MCI, late MCI,
and AD using clinical/neuropsycholgical variables is critical. This information allows us
to evaluate imaging biomarkers as predictors that can define the stage of the disease.
However, to accomplish this goal, large databases are required that follow subjects over
long periods of time, such as the ADNI database. Continued acquisition of standardized
imaging protocols such as MRI, fMRI and PET in such cohorts will be an enormous asset
to assess impact on predictive ability for new imaging analysis methods.

170
5.5 References

1.

Duthey B. Priority Medicines for Europe and the World "A Public Health
Approach to Innovation". Vol 62013:1-74.

2.

Aluise CD, Sowell RA, Butterfield DA. Peptides and proteins in plasma and
cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of
therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta.
2008;1782(10):549-558.

3.

Gold CA, Budson AE. Memory loss in Alzheimer's disease: implications for
development of therapeutics. Expert Rev Neurother. 2008;8(12):1879-1891.

4.

Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging
in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14(11):500.

5.

Vlassenko AG, Benzinger TLS, Morris JC. PET amyloid-beta imaging in
preclinical Alzheimer's disease. Bba-Mol Basis Dis. 2012;1822(3):370-379.

6.

Mattsson N, Tosun D, Insel PS, et al. Association of brain amyloid-beta with
cerebral perfusion and structure in Alzheimer's disease and mild cognitive
impairment. Brain : a journal of neurology. 2014;137(Pt 5):1550-1561.

7.

Tosun D, Joshi S, Weiner MW, the Alzheimer's Disease Neuroimaging I.
Multimodal MRI-based Imputation of the Abeta+ in Early Mild Cognitive
Impairment. Ann Clin Transl Neurol. 2014;1(3):160-170.

8.

Binnewijzend MA, Schoonheim MM, Sanz-Arigita E, et al. Resting-state fMRI
changes in Alzheimer's disease and mild cognitive impairment. Neurobiology of
aging. 2012;33(9):2018-2028.

9.

Brier MR, Gordon B, Friedrichsen K, et al. Tau and Abeta imaging, CSF
measures, and cognition in Alzheimer's disease. Sci Transl Med.
2016;8(338):338ra366.

10.

Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early
progress and future directions. Lancet neurology. 2015;14(1):114-124.

11.

Jones DT, Vemuri P, Murphy MC, et al. Non-stationarity in the "resting brain's"
modular architecture. Plos One. 2012;7(6):e39731.

12.

Damoiseaux JS. Resting-state fMRI as a biomarker for Alzheimer's disease?
Alzheimers Res Ther. 2012;4(2):8.

13.

Cho ZH, Han JY, Hwang SI, et al. Quantitative analysis of the hippocampus using
images obtained from 7.0 T MRI. NeuroImage. 2010;49(3):2134-2140.

171
14.

Eriksson SH, Thom M, Bartlett PA, et al. PROPELLER MRI visualizes detailed
pathology of hippocampal sclerosis. Epilepsia. 2008;49(1):33-39.

15.

Malykhin NV, Lebel RM, Coupland NJ, Wilman AH, Carter R. In vivo
quantification of hippocampal subfields using 4.7 T fast spin echo imaging.
NeuroImage. 2010;49(2):1224-1230.

16.

Wisse LEM, Kuijf HJ, Honingh AM, et al. Automated Hippocampal Subfield
Segmentation at 7T MRI. Am J Neuroradiol. 2016;37(6):1050-1057.

17.

Van Leemput K, Bakkour A, Benner T, et al. Automated segmentation of
hippocampal subfields from ultra-high resolution in vivo MRI. Hippocampus.
2009;19(6):549-557.

18.

den Heijer T, der Lijn F, Vernooij MW, et al. Structural and diffusion MRI
measures of the hippocampus and memory performance. NeuroImage.
2012;63(4):1782-1789.

19.

Jeneson A, Squire LR. Working memory, long-term memory, and medial
temporal lobe function. Learn Mem. 2012;19(1):15-25.

20.

Geuze E, Vermetten E, Bremner JD. MR-based in vivo hippocampal volumetrics:
1. Review of methodologies currently employed. Molecular psychiatry.
2005;10(2):147-159.

21.

Jack CR, Jr., Barkhof F, Bernstein MA, et al. Steps to standardization and
validation of hippocampal volumetry as a biomarker in clinical trials and
diagnostic criterion for Alzheimer's disease. Alzheimer's & dementia : the journal
of the Alzheimer's Association. 2011;7(4):474-485 e474.

22.

Boccardi M, Ganzola R, Bocchetta M, et al. Survey of protocols for the manual
segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI
harmonized protocol. Journal of Alzheimer's disease : JAD. 2011;26 Suppl 3:6175.

23.

Boccardi M, Bocchetta M, Apostolova LG, et al. Establishing magnetic resonance
images orientation for the EADC-ADNI manual hippocampal segmentation
protocol. J Neuroimaging. 2014;24(5):509-514.

24.

Aljabar P, Heckemann RA, Hammers A, Hajnal JV, Rueckert D. Multi-atlas
based segmentation of brain images: Atlas selection and its effect on accuracy.
NeuroImage. 2009;46(3):726-738.

25.

Heckemann RA, Keihaninejad S, Aljabar P, et al. Automatic morphometry in
Alzheimer's disease and mild cognitive impairment. NeuroImage.
2011;56(4):2024-2037.

172
26.

Collins DL, Pruessner JC. Towards accurate, automatic segmentation of the
hippocampus and amygdala from MRI by augmenting ANIMAL with a template
library and label fusion. NeuroImage. 2010;52(4):1355-1366.

27.

Nestor SM, Gibson E, Gao FQ, Kiss A, Black SE. A direct morphometric
comparison of five labeling protocols for multi-atlas driven automatic
segmentation of the hippocampus in Alzheimer's disease. NeuroImage.
2012;66C:50-70.

28.

Gousias IS, Rueckert D, Heckemann RA, et al. Automatic segmentation of brain
MRIs of 2-year-olds into 83 regions of interest. NeuroImage. 2008;40(2):672-684.

29.

Heckemann RA, Hajnal JV, Aljabar P, Rueckert D, Hammers A. Automatic
anatomical brain MRI segmentation combining label propagation and decision
fusion. NeuroImage. 2006;33(1):115-126.

30.

Barnes J, Foster J, Boyes RG, et al. A comparison of methods for the automated
calculation of volumes and atrophy rates in the hippocampus. NeuroImage.
2008;40(4):1655-1671.

31.

Coupe P, Manjon JV, Fonov V, Pruessner J, Robles M, Collins DL. Patch-based
segmentation using expert priors: Application to hippocampus and ventricle
segmentation. NeuroImage. 2011;54(2):940-954.

32.

Pipitone J, Park MT, Winterburn J, et al. Multi-atlas segmentation of the whole
hippocampus and subfields using multiple automatically generated templates.
NeuroImage. 2014;101:494-512.

173

Appendices
Appendix A
Permissions

174

175
Appendix B

Curriculum Vitae
Samaneh Kazemifar, MSc
PhD Candidate
Imaging Research Laboratories
Robarts Research Institute
University of Western Ontario
Medical Biophysics
100 Perth Drive, PO Box 5015, London ON N6A 5K8

EDUCATION

2011-Present

PhD candidate (Medical Biophysics)
University of Western Ontario
Early Detection of Alzheimer Disease using Neuroimaging Biomarkers
Supervisor: Dr. Robert Bartha

2008-2010

MSc (Computer Engineering - Artificial Intelligence)
Shiraz University, Shiraz, Iran

2002-2006

BSc Computer Engineering
Shiraz Azad University, Shiraz, Iran

HONOURS AND AWARDS
2011-Present

Western Graduate Research Scholarship
Awarded to graduate students who enrolled with an average of 80% or above.

PUBLICATIONS
Peer Reviewed Manuscripts
Submitted
1.

Samaneh Kazemifar, Kathryn Manning, Nagalingam Rajakumar, Francisco A. Gómez, Andrea
Soddu, Michael J. Borrie, Ravi S. Menon, and Robert Bartha, Spontaneous blood oxygen level
dependent MRI signal variations are decreased in Alzheimer disease, (submitted to NeuroImage
Clinical Journal)
Under preparation

176
1.

Samaneh Kazemifar, Manuel Montero-Odasso, and Robert Bartha, Combining Measures of Gait
and Cognition to Predict Hippocampal Atrophy in Mild Cognitive Impairment

Published
1.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Automated Algorithm to Measure Changes in Medial Temporal Lobe Volume in
Alzheimer Disease, Journal of NeuroScience Methods, Volume 227(2014), pp. 35–46

2.

Samaneh Kazemifar, Reza Boostani, An Efficient Adaptive Segmentation Algorithm on EEG
signals to Discriminate between Subject with Epilepsy and Normal Control, International Review
on Computers and Software, Vol. 8. n. 1, pp. 256-261

ABSTRACTS AND PRESENTATIONS
Poster Presentations
1.

Samaneh Kazemifar, Kathryn Manning, Nagalingam Rajakumar, Francisco A. Gómez, Andrea
Soddu, Michael J. Borrie, Ravi S. Menon, and Robert Bartha, Neuronal Activity Derived from
Resting State Functional MRI: A Potential Biomarker for Alzheimer Disease, The Alzheimer’s
Association International Conference (AAIC), Toronto, Ontario, Canada, July 2016

2.

Samaneh Kazemifar, Kathryn Manning, Nagalingam Rajakumar, Francisco A. Gómez, Andrea
Soddu, Michael J. Borrie, Ravi S. Menon, and Robert Bartha, Development of a Novel Neuronal
Activity Biomarker for Alzheimer Disease using Resting State fMRI, 8th Canadian Conference on
Dementia (CCD), Ottawa, Ontario, Canada, October 2015

3.

John Drozd, Robert Moreland, Samaneh Kazimafar, Alex Hayes, Amanda Khan, Michael Borrie
and Robert Bartha, Tracking Brain Ventricle Expansion in Alzheimer Disease Using Combined
Intensity and Shape-based Segmentation, poster presented at Alzheimer's Association
International Conference (AIC and AAIC 2012), Vancouver, Canada, July 13-19, 2012

4.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Automated Algorithm to Segment Medial Temporal Lobe Using Deformable Registration
in Early Alzheimer Disease, The London Health Research Day, London, Ontarion, Canada.
February 2012

5.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Automated and Robust Algorithm to Measure Changes in Medial Temporal Lobe Volume
in Early Alzheimer Disease, The Alzheimer’s Association, Alzheimer’s Imaging Consortium
(AIC) Annual Meeting, Vancouver, BC, Canada. July 2012

6.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Automated and Robust Algorithm to Measure Changes in Medial Temporal Lobe Volume
in Early Alzheimer Disease, The Alzheimer’s Association International Conference (AAIC)
Annual Meeting, Vancouver, BC, Canada. July 2012

7.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Novel Multi-Atlas Automatic Segmentation of Medial Temporal Lobe Volume Change in
Alzheimer's Disease, The Alzheimer’s Imaging Consortium (AIC), Boston, MA, July 2013

177

8.

Samaneh Kazemifar, John J. Drozd, Nagalingam Rajakumar, Michael J. Borrie, and Robert
Bartha, Novel Multi-Atlas Automatic Segmentation of Medial Temporal Lobe Volume Change in
Alzheimer's Disease, The Alzheimer’s Association International Conference (AAIC), Boston,
MA, July 2013

Book Chapter
1.

S. Kazemifar, R. Boostani, Use of Time-Frequency Transforms and Kernel PCA to Classify
Epileptic Patients from Control Subjects, (Edited by D.-S. Huang et al.) Springer-Verlag Berlin
Heidelberg (ICIC 2010), LNAI 6216, pp. 465–472

TECHNICAL SKILLS
1.
2.
3.
4.
5.
6.
7.
8.
9.

C++
ITK (Insight Segmentation and Registration ToolKit)
MATLAB toolbox
FSL (FMRIB Software Library) software
SPM (Statistical Parametric Mapping) software
Segmentation and registration methods
Image processing
Signal processing
Machine learning algorithms

WORK EXPERIENCE
2011:

SUMMER STUDENT

•

Research on Hippocampus Segmentation

REFERENCES:
1.

Robert Bartha, PhD
Scientist, Robarts Research Institute
Professor, Department of Medical Biophysics
University of Western Ontario, London, Ontario
Email: rbartha@robarts.ca

2.

Michael Borrie, MB ChB, FRCPC
Professor, Department of Medicine
Division of Geriatric Medicine
University of Western Ontario, London, Ontario
Email: Michael.borrie@sjhc.london.on.ca

